Table 2
Reproductive findings in rats given 1-butanol on days 0–20 of pregnancy

Dose (%)	0 (Control)	0.2	1.0	5.0
No. of litters	20	20	20	20
No. of litters totally resorbed	0	0	0	0
No. of corpora lutea per litter[a]	16.4 ± 3.6	16.7 ± 3.0[d]	16.1 ± 2.1	16.3 ± 2.6
No. of implantations per litter[a]	14.3 ± 2.8	15.1 ± 1.7	15.2 ± 1.2	14.7 ± 2.5
% Preimplantation loss per litter[b]	9.0	9.0[d]	4.4	9.2
% Postimplantation loss per litter[c]	6.0	5.4	3.7	8.0
No. of live fetuses per litter[a]	13.4 ± 2.6	14.3 ± 1.4	14.7 ± 1.5	13.5 ± 2.5
Sex ratio of live fetuses (male/female)	128/139	145/140	149/144	131/139
Body weight of live fetuses (g)[a]				
Male	4.18 ± 0.27	4.00 ± 0.24	4.04 ± 0.25	3.83 ± 0.18**
Female	3.97 ± 0.25	3.86 ± 0.20	3.83 ± 0.16	3.59 ± 0.17**
Fetal crown-rump length (mm)[a]				
Male	40.5 ± 1.2	40.3 ± 1.4	40.2 ± 1.2	39.7 ± 1.3
Female	39.4 ± 1.2	39.4 ± 1.2	39.3 ± 1.1	38.5 ± 1.4
Placental weight (g)				
Male	0.50 ± 0.05	0.49 ± 0.05	0.48 ± 0.06	0.50 ± 0.06
Female	0.49 ± 0.05	0.48 ± 0.05	0.47 ± 0.05	0.49 ± 0.06

** Significantly di erent from the control, $P < 0.01$.
[a] Values are given as the mean ± SD.
[b] (No. of preimplantation embryonic loss/no. of corpora lutea) 100.
[c] (No. of resorptions and dead fetuses/no. implantations) 100.
[d] Value was obtained from 19 pregnant rats.

revealed one fetus with supernumerary thoracic vertebral bodies and malpositioned thoracic vertebrae at 1.0%. Although the total number of fetuses with skeletal variations was significantly increased at 5.0%, the number of fetuses with individual skeletal variations was not significantly increased, except for fetuses with short supernumerary ribs at 5.0%. A significantly lower number of forepaw proximal phalanges was observed at 5.0%. Membranous ventricular septum defect occurred in one fetus of the control and 0.2% groups and 3 fetuses in 3 dams of the 5.0% group. One fetus with a double aorta in the control group and one fetus with a left umbilical artery in the control and 2.0% groups were observed. Thymic remnants in the neck were found in 4–11 fetuses of the control and groups treated with 1-butanol. However, there was no significant di erence in the incidence of fetuses with internal abnormalities between the control and groups treated with 1-butanol.

4. Discussion

The present study was conducted to determine the developmental toxicity of 1-butanol and designed to replicate the observations of the study by Sitarek et al. (1994). The data showed that prenatal administration of 1-butanol did not produce morphological anomalies in fetuses of rats. Thus, we have been unable to confirm the results of Sitarek s study in which prenatal exposure to 1-butanol produced fetal anomalies.

The doses of 1-butanol used in the present study expected to induce maternal and/or developmental toxicity, such as a decrease in maternal body weight gain and fetal weight, were given to pregnant rats during the whole period of pregnancy to characterize the e ects of 1-butanol on embryonic/fetal development. Maternal toxicity, a significant decrease in body weight gain, was found at 5.0%. Maternal food and water consumptions were also reduced in this dose group. Although the only significant decrease in maternal body weight gain was observed on days 0–2 of pregnancy at 1.0%, this decrease was occasional and discontinuous and seems unlikely to be of toxicological significance. In this dose group, decreases in the maternal food consumption during the whole period of pregnancy and water consumption during the early period of pregnancy, which were unaccompanied by the continuous changes in body weight gain, were observed. No significant changes in maternal parameters were noted in the 0.2% group. These findings in maternal rats indicate that 1-butanol exerts maternal toxicity at 5.0% (equivalent to 5654 mg/kg/day) when administered during the entire period of pregnancy in rats.

No significant increase in the incidence of postimplantation loss was found at any dose of 1-butanol, and significantly decreased weights of male and female fetuses were found at 5.0%. No significant adverse effects on reproductive parameters were detected at 0.2% and 1.0%. These findings indicate that 1-butanol is not toxic to embryonic/fetal survival up to 5.0% or fetal growth up to 1.0% when administered during the whole period of pregnancy.

As for morphological examinations in the fetuses of exposed mothers, a few fetuses with external, skeletal

Table 3
Morphological examinations in fetuses of rats given 1-butanol on days 0–20 of pregnancy

Dose (%)	0 (Control)	0.2	1.0	5.0
External examination				
Total no. of fetuses (litters) examined	267 (20)	285 (20)	293 (20)	270 (20)
Total no. of fetuses (litters) with abnormalities	1 (1)	1 (1)	0	0
Spina bifida	1 (1)	0	0	0
Thread-like tail and anal atresia	0	1 (1)	0	0
Skeletal examination				
Total no. of fetuses (litters) examined	139 (20)	147 (20)	152 (20)	140 (20)
Total no. of fetuses (litters) with abnormalities	0	0	1 (1)	0
Supernumerary of thoracic vertebral bodies and malpositioned thoracic vertebrae	0	0	1 (1)	0
Total no. of fetuses (litters) with variations	28 (11)	23 (12)	52 (17)	69 (20)**
Bipartite ossification of thoracic centra	1 (1)	1 (1)	1 (1)	7 (5)
Dumbbell ossification of thoracic centra	0	1 (1)	2 (2)	3 (3)
Bipartite ossification of lumbar centra	0	0	0	2 (2)
Supernumerary lumbar vertebrae	4 (1)	1 (1)	5 (3)	5 (2)
Lumbarization	0	0	1 (1)	1 (1)
Bipartite ossification of sternebrae	1 (1)	1 (1)	1 (1)	1 (1)
Misaligned sternebrae	0	0	0	1 (1)
Cervical ribs	2 (2)	3 (3)	3 (3)	7 (5)
Full supernumerary ribs	5 (2)	1 (1)	10 (5)	9 (5)
Short supernumerary ribs	20 (10)	18 (9)	43 (16)	55 (19)**
Wavy ribs	0	0	0	1 (1)
Degree of ossification[a]				
No. of sacral and caudal vertebrae	8.4 ± 0.5	8.4 ± 0.4	8.3 ± 0.5	8.1 ± 0.3
No. of sternebrae	5.9 ± 0.2	5.8 ± 0.2	5.8 ± 0.2	5.8 ± 0.2
No. of forepaw proximal phalanges	1.6 ± 1.3	1.6 ± 0.9	1.2 ± 1.1	0.3 ± 0.4**
Internal examination				
Total no. of fetuses (litters) examined	128 (20)	138 (20)	141 (20)	130 (20)
Total no. of fetuses (litters) with abnormalities	7 (6)	9 (6)	11 (8)	14 (9)
Membranous ventricular septum defect	1 (1)	1 (1)	0	3 (3)
Double aorta	1(1)	0	0	0
Left umbilical artery	1 (1)	0	1 (1)	0
Thymic remnant in neck	4 (4)	8 (5)	10 (8)	11 (8)

** Significantly di erent from the control, $P < 0.01$.
[a] Values are given as the mean ± SD.

and/or internal abnormalities were found in all groups. The abnormalities observed in the present study are not thought to be due to the administration of 1-butanol, because they have occurred at a very low incidence and are of types that occur sporadically among control rat fetuses (Kameyama et al., 1980; Morita et al., 1987; Nakatsuka et al., 1997; Barnett et al., 2000). Several types of skeletal variations were also found in the control and groups treated with 1-butanol. These skeletal variations are frequently observed in fetuses of rats at term (Kimmel and Wilson, 1973; Kameyama et al., 1980; Morita et al., 1987; Nakatsuka et al., 1997; Barnett et al., 2000). In the 5.0% group, a significant increase in the incidence of fetuses with skeletal variations and fetuses with short supernumerary ribs, but not full supernumerary ribs, and a significant decrease in the degree of ossification were accompanied by a significant decrease in the fetal weight. These findings show a correlation between these morphological alterations and growth retardation in fetuses. Although a skeletal variation, i.e., full supernumerary ribs, is a warning sign of possible teratogenicity, short supernumerary ribs, sternebral variations, and bilobed centra of the vertebral column are normal variations (Kimmel and Wilson, 1973). Chahoud et al. (1999) noted that variations are unlikely to adversely a ect survival or health and this might result from a delay in growth or morphogenesis that has otherwise followed a normal pattern of development. Consideration of these findings together suggests that the morphological changes in fetuses observed in the present study do not indicate a teratogenic response and that 1-butanol possesses no teratogenic potential in rats.

In Sitarek s study (1994), significant increases in the incidences of wavy ribs at 300 mg/kg/day, dilation of the subarachnoid space and dilation of the lateral ventricle and/or third ventricle of the brain at 300 mg/kg/day and higher, dilation of the renal pelvis and external hydrocephaly at 1000 mg/kg/day, internal hydrocephaly at 1000 mg/kg/day and higher, and supernumerary ribs and delayed ossification at 5000 mg/kg/day were found. A significant decrease in fetal crown-rump length was

also observed at 5000 mg/kg/day. Based on these findings, Sitarek et al. (1994) concluded that 1-butanol had adverse e ects on the morphological development of fetuses in rats. However, we did not confirm their findings. We have demonstrated here that prenatal 1-butanol has no adverse e ect on the morphological development of rat o spring. There are some di erences between Sitarek s study and the present study in experimental conditions, such as duration of administration and rat strain used in the experiments. Sitarek et al. (1994) administered 1-butanol to female rats for 8 weeks before mating and throughout the mating and pregnancy period and found fetal anomalies, such as hydrocephaly and dilation of the cerebral ventricles and the renal pelvis. On the other hand, we gave 1-butanol to female rats during the whole period of pregnancy and did not detect fetuses with these anomalies. Administration during the premating and mating period is thought to be excluded from the susceptible period for induction of morphological anomalies such as hydrocephaly/dilation of the cerebral ventricles and dilation of the renal pelvis, because rat fetuses are susceptible to induction of these anomalies during mid and late pregnancy (Wood and Hoar, 1972; Kameyama, 1985). The strain di erence of rats used in the experiments may explain the discrepancy in the findings regarding fetal anomalies between the studies. In Sitarek s study (1994), ImP: DAK rats obtained from their own breeding colony were used. No detailed information on this strain of rats was available (Sitarek et al., 1994). In their study, dilation of the lateral ventricle and/or third ventricle of the brain was observed in 2% of fetuses (one of the 12 litters) in the control group. In their another study using Imp: DAK rats, extension of the lateral ventricle and/or third ventricle of the brain was observed in 11.7% of fetuses (8 of the 17 litters) in the control group (Sitarek et al., 1996). However, these anomalies were not found in the control group of their studies using Wistar rats (Baranski et al., 1982), Imp: Lodz rats (Sitarek, 1999, 2001) and Imp: WIST rats (Sitarek and Sapota, 2003). The incidences of dilation of the cerebral ventricles in Imp: DAK rats are thought to be higher than those in the background control data of other strains of rats. The fetal incidence of hydrocephaly/dilation of cerebral ventricles in the control rats of reproductive studies conducted between 1986 and 1993 in 63 research institutes is reported to be 0–0.09% and 0–0.26%, respectively (Nakatsuka et al., 1997). In Crj: CD (SD) IGS rats which were used in the present study, the incidence of dilation of the lateral ventricles of the brain in 19 studies conducted during 1998–2000 is reported to be 0–0.06% in fetuses and 0–0.44% in litters (Barnett et al., 2000). Thus, hydrocephaly/dilation of the cerebral ventricle is not commonly observed in fetuses of common strains of rats.

The di erence in terminology used for classification of structural anomalies in fetuses may also explain the discrepancy in the findings regarding fetal anomalies between the studies. Sitarek et al. (1996) stated that minor abnormalities, such as enlarged lateral ventricle and/or third ventricle, are quite frequent in rat fetuses and without having the dose-dependent relationship should not be taken alone as evidence of tested chemical fetotoxicity. However, the Fourth Berlin Workshop on Terminology in Developmental Toxicity noted that changes a ecting brain ventricles are more likely to be classified as malformations and classification should be based on the historical control incidences, the nature of the organ a ected and the severity (Solecki et al., 2003). In Sitarek s study (1994), dilation of the subarachnoid space was observed in fetuses of rats given 1-butanol at 300 mg/kg/day and higher. This anomaly was also found in fetuses in Imp: DAK rats given *N*-cyclohexyl-2-benzothiazolesulfenamide (Sitarek et al., 1996) and Imp: Lodz rats given *N*-methylmorpholine (Sitarek, 1999). No information on the definition of this anomaly was available in their reports. We are unaware of this anomaly in other literature (Kameyama et al., 1980; Morita et al., 1987; Nakatsuka et al., 1997; Horimoto et al., 1998; Barnett et al., 2000; Solecki et al., 2003).

In conclusion, the administration of 1-butanol to pregnant rats throughout pregnancy had adverse e ects on maternal rats and embryonic/fetal growth but had no adverse e ects on fetal morphological development even at a maternally toxic dose. The data indicate that 1-butanol induces developmental toxicity only at maternally toxic doses in rats. Based on the significant decreases in maternal body weight gain and fetal weight at 5.0%, it is concluded that the NOAELs of 1-butanol for both dams and fetuses are 1454 mg/kg/day (1.0% in drinking water) in rats.

Acknowledgment

This study was performed in 2003 through 2004 at the Ina Research, Inc. (Ina, Japan) and supported by the Ministry of Health, Labour and Welfare, Japan.

References

Baranski, B., Stetkiewicz, I., Trzcinka-Ochocka, M., Sitarek, K., Szymczak, W., 1982. Teratogenicity, fetal toxicity and tissue concentration of cadmium administered to female rats during organogenesis. Journal of Applied Toxicology 2, 255–259.

Barnett Jr., J.F., Lewis, D., Tappen, A., Hoberman, A.M., Christian, M.S., 2000. Reproductive indices, fetal gross, visceral and skeletal alterations, sexual maturation, passive avoidance and water maze data, a comparison of results in CD(SD)IGS rats and CD(SD) rats. In: Matsuzawa, T., Inoue, H. (Eds.), Biological Reference Data on CD (SD)IGS Rats-2000. CD(SD)IGS Study Group, c/o Charles River Japan Inc., Yokohama, Japan.

Chahoud, I., Buschmann, J., Clark, R., Druga, A., Falke, H., Faqi, A., Hansen, E., Heinrich-Hirsch, B., Helleig, J., Lingk, W., Parkinson,

M., Paumgartten, F.J.R., Pefil, R., Platzek, T., Scialli, A.R., Seed, J., Stahlmann, R., Ulbrich, B., Wu, X., Yasuda, M., Younes, M., Solecki, R., 1999. Classification terms in developmental toxicology: need for harmonization. Report of the second workshop on the terminology in developmental toxicology Berlin, 27–28 August 1998. Reproductive Toxicology 13, 77–82.

Dawson, A.B., 1926. A note on the staining of the skeleton of cleared specimens with arizarin red-S. Stain Technology 1, 123–124.

Dunnett, C.W., 1955. A multiple comparison procedure for comparing several treatments with control. Journal of American Statistical Association 50, 1096–1121.

Horimoto, M., Ariyuki, F., Daidohji, S., Fujii, T., Fukunishi, K., Hanada, S., Ikegami, S., Ishii, H., Inoue, T., Iwase, T., Matsuura, M., Matsuzawa, T., Nishi, N., Ohkubo, Y., Sanbuissho, A., Sekiya, K., Tani, M., Taniguchi, H., Yokomoto, Y., Yoshida, J., Takahashi, M., Yasuda, M., 1998. Terminology of developmental abnormalities in common laboratory mammals (Japanese version 1). Congenital Anomalies 38, 153–237 (Japanese).

IPCS/WHO (International Programme on Chemical Safety/World Health Organization), 1987. Environmental Health Criteria 65. Butanols: Four Isomers: 1-Butanol, 2-Butanol, *tert*-Butanol, Isobutanol. WHO, Geneva.

Kameyama, Y., 1985. Comparative developmental pathology of the central nervous system. In: Marois, M. (Ed.), Prevention of Physical and Mental Congenital Defects. Part A: The Scope of the Problem. Alan R. Liss, New York.

Kameyama, Y., Tanimura, T., Yasuda, M. (Eds.), 1980. Spontaneous malformations in laboratory animals-photographic atlas and reference data. Congenital Anomalies 20, 25–106 (Japanese).

Kimmel, C.A., Wilson, G.J., 1973. Skeletal deviations in rats: Malformations or variations? Teratology 8, 309–316.

MHW, Japan (Ministry of Health and Welfare, Japan), 1997a. Guidelines for Toxicity Studies of Drugs.

MHW, Japan (Ministry of Health and Welfare, Japan), 1997b. The GLP Standards for Non-clinical Safety Studies on Drugs, MHW Ordinance no. 21.

Morita, H., Ariyuki, F., Inomata, N., Nishimura, K., Hasegawa, Y., Miyamoto, M., Watanabe, T., 1987. Spontaneous malformations in laboratory animals: frequency of external, internal and skeletal malformations in rats, rabbits and mice. Congenital Anomalies 27, 147–206.

Nakatsuka, T., Horimoto, M., Ito, M., Matsubara, Y., Akaike, M., Ariyuki, F., 1997. Japan Pharmaceutical Manufacturers Association (JPMA) survey on background control data of developmental and reproductive toxicity studies in rats, rabbits and mice. Congenital Anomalies 37, 47–138.

Nelson, B.K., Brightwell, W.S., Khan, A., Burg, J.R., Goad, P.T., 1989a. Lack of selective developmental toxicity of three butanol isomers administered by inhalation to rats. Fundamental and Applied Toxicology 12, 469–479.

Nelson, B.K., Brightwell, W.S., Robertson, S.K., Khan, A., Krieg Jr., E.F., Massari, V.J., Burg, 1989b. Behavioral teratology investigation of 1-butanol in rats. Neurotoxicology and Teratology 11, 313–315.

Nishimura, K., 1974. A microdissection method for detecting thoracic visceral malformations in mouse and rat fetuses. Congenital Amomalies 14, 23–40 (Japanese).

Sitarek, K., 1999. Maternal and fetal toxicity of *N*-methylmorpholine by oral administration in rats. Teratogenesis, Carcinogenesis, and Mutagenesis 19, 369–376.

Sitarek, K., 2001. Embryolethal and teratogenic e ects of carbendazim in rats. Teratogenesis, Carcinogenesis, and Mutagenesis 21, 335–340.

Sitarek, K., Berlinska, B., Baranski, B., 1994. Assessment of the e ect of *n*-butanol given to female rats in drinking water on fertility and prenatal development of their o spring. International Journal of Occupational Medicine and Environmental Health 7, 365–370.

Sitarek, K., Berlinska, B., Baranski, B., 1996. E ect of oral Sulfenamide TS administration on prenatal development in rats. Teratogenesis Carcinogenesis and Mutagenesis 16, 1–6.

Sitarek, K., Sapota, A., 2003. Maternal-fetal distribution and prenatal toxicity of 2,2,4-trimethyl-1,2-dihydroquinoline in the rat. Birth Defects Research, Part B 68, 375–382.

Snedecor, G.W., Cochran, W.G., 1980. Statistical Methods, seventh ed. Iowa State University Press.

Solecki, R., Bergmann, B., Bürgin, H., Buschmann, J., Clark, R., Druga, A., Van Duijnhoven, E.A.J., Duverger, M., Edwards, J., Freudenberger, H., Guittin, P., Hakaite, P., Heinrich-Hirsch, B., Hellwig, J., Hofmann, T., Hübel, U., Khalil, S., Klaus, A., Kudicke, S., Lingk W., Meredith, T., Moxon, M., Müller, S., Paul, M., Paumgartten, F., Röhrdanz, E., Pfeil, R., Rauch-Ernst, M., Seed, J., Spezia, F., Vickers, C., Woel el, B., Chahoud, I., 2003. Harmonization of rat fetal external and visceral terminology and classification: Report of the Fourth Workshop on the Terminology in Developmental Toxicology, Berlin, 18–20 April 2002. Reproductive Toxicology, 17, 625–637.

Wilson, J.G., 1973. Methods for administering agents and detecting malformations in experimental animals. In: Wilson, J.G., Warkany, J. (Eds.), Teratology: Principles and Techniques. The University of Chicago Press, Chicago, pp. 262–277.

Wood, D.C., Hoar, R.M., 1972. Apparently hydronephrosis as a normal aspect of renal development in late gestation of rats: the e ect of methyl salicylate. Teratology 6, 191–196.

ORIGINAL ARTICLE

Comparative susceptibility of newborn and young rats to six industrial chemicals

Ryuichi Hasegawa, Mutsuko Hirata-Koizumi, Mika Takahashi, Eiichi Kamata, and Makoto Ema
National Institute of Health Sciences, Tokyo, Japan

ABSTRACT **To elucidate the comparative susceptibility of newborn rats to chemicals, newborn and young animals were administered six industrial chemicals by gavage from postnatal days (PND) 4 to 21, and for 28 days starting at 5–6 weeks of age respectively, under the same experimental conditions as far as possible. As two new toxicity endpoints specific to this comparative analysis, presumed no-observed-adverse-effect-levels (pNOAELs) were estimated based on results of both main and dose-finding studies, and presumed unequivocally toxic levels (pUETLs) were also decided. pNOAELs for newborn and young rats were 40 and 200 for 2-chlorophenol, 100 and 100 for 4-chlorophenol, 30 and 100 for p-(α,α-dimethylbenzyl) phenol, 100 and 40 for (hydroxyphenyl)methyl phenol, 60 and 12 for trityl chloride, and 100 and 300 mg/kg/day for 1,3,5-trihydroxybenezene, respectively. To determine pUETLs, dose ranges were adopted in several cases because of the limited results of experimental doses. Values for newborn and young rats were thus estimated as 200–250 and 1000 for 2-chlorophenol, 300 and 500 for 4-chlorophenol, 300 and 700–800 for p-(α,α-dimethylbenzyl) phenol, 140–160 and 1000 for (hydroxyphenyl)methyl phenol, 400–500 and 300 for trityl chloride, and 500 and 1000 mg/kg/day for 1,3,5-trihydroxybenzene, respectively. In most cases, newborn rats were 2–5 times more susceptible than young rats in terms of both the pNOAEL and the pUETL. An exception was that young rats were clearly more susceptible than their newborn counterparts for trityl chloride.**

Key Words: industrial chemicals, newborn rats, susceptibility

INTRODUCTION

In risk assessment of chemicals, the no-observed-adverse-effect-level (NOAEL) determined with repeated dose toxicity studies is generally divided by uncertainty factors (UFs) to obtain the tolerable daily intake (TDI) (Hasegawa *et al.* 2004). UFs include inter- and intraspecies differences, lack of data quality and the nature of observed toxicity. As TDI is an allowable lifetime exposure level for a chemical, at which no appreciable health risk would be expected over a lifetime, the NOAEL must be derived from lifetime exposure studies and appropriate reproductive/developmental studies, or their equivalents. Administration generally starts at the prepubertal stage (4–5 weeks old) or with young adults (10–12 weeks old) in rodent studies. Therefore, the suckling phase is the major remaining period where animals are not directly administered to chemicals. If susceptibility of infant animals to chemicals via direct exposure was evidenced by appropriate comparative studies, the results would preferably be incorporated into the UF as one justification for lack of data quality.

In the latest decade, infant and child health has become a major focus (Landrigan *et al.* 2004), especially since endocrine disrupters became a contentious issue around the world (IPCS 2002). Since there are distinct differences in characteristics from the adult case (Dourson *et al.* 2002), particular attention must be paid to infant and child health. The Japanese government has therefore incorporated the newborn rat study (newborn study) into Existing Chemical Safety Programs as an especial project to comparatively determine susceptibility to 18 industrial chemicals. As the core of this program is to conduct 28-day repeated dose toxicity studies using young rats (young study) with untested chemicals from the existing list, chemicals for newborn studies were selected among the chemicals scheduled for young studies in the same year for the best comparison of data. Furthermore, we have had to newly establish a newborn rat study protocol because of the lack of any standard testing guidelines. Major differences of newborn from young studies are a shorter administration period (18 days only for the suckling phase) and additional examination of early functional, external and sexual development (Koizumi *et al.* 2001). Studies were conducted from 1995 to 1998 and we have already reported the results of comparative analysis for eight chemicals, showing newborn rats to be generally 2–4 fold more susceptible than young rats in most cases on basis of NOAEL and the unequivocally toxic level (UETL), the latter being uniquely defined in this program as doses inducing clear clinical toxic signs, death or critical histopathological damage (Koizumi *et al.* 2001, 2002, 2003; Fukuda *et al.* 2004; Takahashi *et al.* 2004; Hirata-Koizumi *et al.* 2005).

The purpose of this study is to obtain additional information on susceptibility of newborn rats to other chemicals. Here we selected the following six industrial chemicals, mostly phenolic compounds: 2-chlorophenol, 4-chlorophenol, p-(α,α-dimethylbenzyl) phenol (hydroxyphenyl)methyl phenol, trityl chloride and 1,3,5-trihydroxybenzene, because of structural similarity to endocrine-disrupting phenols, bisphenol A (Takahashi & Oishi 2001), and nonylphenol (Lee 1998). These chemicals have been used as an intermediate in dyes and an ingredient in pesticides (2-chlorophenol), an intermediate in dyes, bactericides and an ingredient in cosmetics (4-chlorophenol), an ingredient in surfactants, bactericides, an intermediate in pesticides and plasticizers (p-(α,α-dimethylbenzyl) phenol), an ingredient in resins ((hydroxyphenyl)methyl phenol), an intermediate in medicines (trityl chloride) and an ingredient in medicines, a stabilizer of synthetic rubbers and an adhesive of rubbers (1,3,5-trihydroxybenzene) (Chemical Products' Handbook 2004). Under the same experimental conditions as far as possible, we have examined the repeated dose toxicity of these chemicals in newborn and young rats and compared susceptibility for each. Previously we had applied NOAEL and UETL as estimated doses

Correspondence: Ryuichi Hasegawa, PhD, Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-1, Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan. Email: hasegawa@nihs.go.jp
Received May 16, 2005; revised and accepted July 6, 2005.

or ranges of doses for comparison of chemical susceptibility, but we have decided to employ the new terminology of presumed NOAEL (pNOAEL) and presumed UETL (pUETL) in their place. As a result, in most cases newborn rats were more susceptible to these industrial chemicals than young rats in terms of both pNOAEL and pUETL.

MATERIALS

2-Chlorophenol (CAS no. 95-57-8, Lot no. OJL-15, purity: 99.49%) was obtained from Inui Corporation and prepared in olive oil; 4-chlorophenol (CAS no. 106-48-9, Lot no. PJF-3, purity: 99.29%) from Inui Corporation and in corn oil; p-(α,α-dimethylbenzyl) phenol (CAS no. 599-64-4, Lot no. 101002, purity: 99.88%) from Sun TechnoChemical Inc. in olive oil; (hydroxyphenyl)methyl phenol (CAS no. 1333-16-0, Lot no. S980013, purity: 99.0% [2,2′ isomer 14–18%, 2,4′ isomer 44–48%, 4,4′ isomer 26–32%]) from Mitsui Chemicals, Inc. in 0.5% CMC-Na solution containing 0.1% Tween 80; trityl chloride (CAS no. 76-83-5, Lot no. 1038, purity: 99.5%) from Kurogane Kasei Co. Ltd. in olive oil; and 1,3,5-trihydroxybenzene (CAS no. 108-73-6, Lot no. OS-12074, purity: 99.9%) from Ishihara Sangyou Co., Ltd. in olive oil. Test solutions were prepared at least once a week and were kept cool and in the dark until dosing. The stability was confirmed to be at least seven days under these conditions. All other reagents used in this study were specific purity grade.

METHODS

All animal studies were performed in five testing laboratories contracted to the Japanese Government, after we approved the test protocol.

Animals

Sprague-Dawley SPF rats [Crj:CD(SD)IGS] were purchased from Charles River Japan Inc. (Kanagawa, Japan) and maintained in an environmentally controlled room at 24 ± 2°C with a relative humidity of 55 ± 15%, a ventilation rate of more than 10 times per hour, and a 12:12 h light/dark cycle. For the studies of newborns, 20 pregnant rats (shipped in at gestation day 14) were allowed to deliver spontaneously. All newborns were separated from dams on postnatal day (PND) 3 and groups of 12 males and 12 females were selected and assigned to each of the four dose groups, including the controls. Twelve foster mothers were selected based on health and nursing conditions, and suckled the four males and four females assigned to each group up to weaning on PND 21 (termination of dosing and autopsy for half of the animals). After weaning, the rest of the animals for the recovery-maintenance group (see Study Design) were individually maintained for nine weeks. In the studies of young, four-week-old male and female rats were obtained and used at ages of 5–6 weeks after acclimation. All animals were allowed free access to a basal diet and water.

Study design (time schedule as described previously [Koizumi *et al.* 2001])

1. 18-day repeated dose study in newborn rats (newborn study)

In a dose-finding study, chemicals were administered by gastric intubation to newborn male and female rats on PNDs 4–21. Animals were examined for general behavior and body weights during the dosing period, and sacrificed at PND 22 for assessment of hematology, blood biochemistry, macroscopic findings and organ weights.

In the main study, newborn rats (12/sex/dose) were administered chemicals by gastric intubation on PNDs 4–21, the dosage being set on the basis of results of the dose-finding study. On PND 22, half of the animals were sacrificed and the rest were maintained for nine weeks without chemical treatment, and then sacrificed at 12 weeks of age (the recovery-maintenance group). During the study, general behavior and body weight were examined at least once a day and each week, respectively. In addition, developmental parameters were assessed, such as surface righting and visual placing reflex for reflex ontogeny, fur appearance, incisor eruption and eye opening for external development, and preputial separation, vaginal opening and estrous cycle for sexual development. Urinalysis (color, pH, occult blood, protein, glucose, ketone bodies, bilirubin, urobilinogen, sediment, volume of the urine and osmotic pressure) was conducted in the late recovery-maintenance period.

At weaning age PND 22 after the last treatment, blood was collected under anesthesia from the abdomen of all animals in the scheduled-sacrifice group. In the recovery-maintenance group, this was conducted at 85 days of age after overnight starvation. Blood was examined for hematological parameters such as the red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, white blood cell count, platelet count, reticulocyte count and differential leukocyte count, and for biochemistry (total protein, albumin, albumin/globulin ratio, glucose, total cholesterol, triglycerides, phospholipid, total bilirubin, urea nitrogen (BUN), creatinine, aspartate aminotransferase, alanine animotransferase (ALT), alkaline phosphatase, γ-glutamyl transpeptidase (γ-GTP), calcium, inorganic phosphorus, sodium, potassium and chlorine). Prothrombin time and activated thromboplastin time were examined only in the recovery-maintenance group. The brain, pituitary gland, thymus, thyroids, heart, lungs, liver, spleen, kidneys, adrenals, testes, epididymides, ovaries and uterus were weighed, and these, with other macroscopically abnormal organs, were fixed in 10% buffered formalin-phosphate (following Bouin's fixation for testes and epididymides). Paraffin sections were routinely prepared and stained with hematoxylin-eosin for microscopic examination. All studies were conducted in compliance with the Good Laboratory Practice Act of the Japanese Government.

2. 28-day repeated dose study in young rats (young study)

In a dose-finding study, chemicals were administered by gastric intubation to five-week-old male and female rats for 14 days. The general behavior, body weight and food consumption were examined, and the animals were sacrificed the day after the last treatment for assessment of hematology, blood biochemistry, macroscopic findings and organ weights.

In the main study, 5–6 week old male and female rats were given chemicals by gastric intubation daily for 28 days and sacrificed after overnight starvation following the last treatment (scheduled-sacrifice group). Recovery groups were maintained for two weeks without chemical treatment and sacrificed at 11 or 12 weeks of age. Rats were examined for general behavior, body weight, food consumption, urinalysis, hematology and blood biochemistry, necropsy findings, organ weights and histopathological findings in compliance with the Test Guideline in the Japanese Chemical Control Act (Official Name: Law Concerning the Examination and Regulation of Manufacture, etc. of Chemical Substances) under Good Laboratory Practice conditions.

Statistical analysis

Quantitative data were analyzed by Bartlett's test (Bartlett 1937) for homogeneity of distribution. When homogeneity was recog-

nized, Dunnett's test (Dunnett 1964) was conducted for comparison between control and individual treatment groups. If not homogenous, the data were analyzed using Steel's multiple comparison test (Steel 1959) or the mean rank test of the Dunnett type (Hollander & Wolfe 1973). For qualitative data such as histopathological findings, the Mann–Whitney's *U*-test (Mann & Whitney 1947) or the Fisher's exact test (Fisher 1973) were performed.

Adoption of pNOAEL and pUETL

NOAEL is a measure used in toxicity studies for the greatest dose at which no adverse effects are observed. No toxicologically meaningful changes are excluded for any grounds, including increase of relative organ weights without any other related changes. As the present purpose was to elucidate susceptibility of newborn rats to chemicals as compared with young rats as accurately as possible, simple application of NOAELs obtained from newborn and young main studies was considered not to be necessarily appropriate even though the dose setting is pertinent. Therefore, we newly defined a pNOAEL as the most likely estimated no-adverse-effect-dose on the basis of data from both main and dose-finding studies. As urinalysis and histopathological examination were not conducted in both dose-finding studies, and the administration period in young dose-finding study was half of the main study, we carefully weighed how the results from the dose-finding study should be taken into account, especially concerning the type of toxicity. In order to consider equivalently toxic intensity doses for newborn and young rats, we also newly defined a pUETL, although this is not without problems given the limited dose points. Therefore, in the most cases, the appropriate pUETL for either newborn or young rats was chosen first, thereafter the matching pUETL or the range of pUETL was speculated to assess equivalent toxicity, considering the entire body of data.

RESULTS

2-Chlorophenol (Table 1)

The newborn investigation was conducted at doses of 0, 20, 100, and 500 mg/kg for the dose-finding and 0, 8, 50, and 300 mg/kg for the main study. The young investigation was conducted at doses of 0, 100, 200, and 500 mg/kg for the dose-finding and 0, 8, 40, 200, and 1000 mg/kg for the main study.

Major toxic effects on the central nervous system (CNS) were found in both sexes of newborn and young rats. In the newborn study, tremors appeared within five minutes and disappeared within four hours in most animals at 300 mg/kg. Hypoactivity and an abnormal gait were also observed in a few cases. The histopathological examination showed slight to moderate basophilic renal tubules in more than half the animals of both sexes, without relative kidney weight changes (increase by 8% for males, 4% for females). In addition to these effects, the body weights of both sexes at this dose were transiently decreased. At 50 mg/kg, only one female showed tremors once from 15 to 30 minutes on day nine after the dosing start. There were no chemical-related changes in developmental parameters. In the young study, most animals of both sexes sporadically showed various effects on the CNS such as tremors, hypoactivity, and an abnormal gait within three hours after dosing at 1000 mg/kg. Most animals also exhibited slight centrilobular hypertrophy of hepatocytes, suggesting a compensatory response to a requirement for hepatic metabolism. In the dose-finding study, no toxic signs were observed, but the information was limited because of the small number of animals, the short administration period, and the lack of histopathological examination. There were no chemical-related abnormalities at 200 mg/kg in the main study.

Although the NOAEL was 8 mg/kg/day for newborn rats based on the main study results, this value was concluded to be too low

Table 1 Toxicity findings for 2-chlorophenol in the newborn and young rat main studies

	Newborn study (mg/kg)					Young study (mg/kg)			
	0	20†	50	100†	300	0	200	500†	1000
Male									
General behavior									
Tremors	0/12	0/4	0/12	0/4	11/12	0/12	0/12	0/3	4/12
Hypoactivity	0/12	0/4	0/12	0/4	2/12	0/12	0/12	0/3	8/12
Abnormal gait	0/12	0/4	0/12	0/4	1/12	0/12	0/12	0/3	4/12
Histopathology									
Renal tubules, basophilic	0/6	no data	0/6	no data	4/6	0/6	0/6	no data	0/6
Centrilobular hypertrophy	0/6	no data	0/6	no data	0/6	0/6	0/6	no data	6/6
Female									
General behavior									
Tremors	0/12	0/4	1/12	0/4	12/12	0/12	0/12	0/3	5/12
Hypoactivity	0/12	0/4	0/12	0/4	3/12	0/12	0/12	0/3	5/12
Abnormal gait	0/12	0/4	0/12	0/4	1/12	0/12	0/12	0/3	7/12
Histopathology									
Renal tubules, basophilic	0/6	no data	0/6	no data	5/6	0/6	0/6	no data	0/6
Centrilobular hypertrophy	0/6	no data	0/6	no data	0/6	0/6	0/6	no data	5/6

Only data for items showing change are included in this table. Data are numbers of animals with the change of the total examined. †indicates dose and data from the dose-finding study. All newborn animals died by the 9th dosing day at 500 mg/kg in the dose-finding study. Body weights of both sexes were only transiently, but not finally reduced, at 300 mg/kg in the newborn main study. Clinical signs in newborn rats were not observed at doses of 20 and 100 mg/kg in the dose-finding study.

because of the absence of clinical signs at 20 and 100 mg/kg in the dose-finding study, and only one female showed tremors once at 50 mg/kg in the main study. The pNOAEL for newborn rats was therefore estimated to be 40 mg/kg/day, a little below the 50 mg/kg. For young rats, the pNOAEL can be considered to be 200 mg/kg/day because of the limited information at 500 mg/kg in the dose-finding study. The toxicity at 300 mg/kg for newborn rats seemed to be slightly higher than that at 1000 mg/kg for young rats, because of the transient depression of body weight found limited to the former cases, although the toxicity profile regarding the CNS was very similar in newborn and young rats. The dose for newborn rats showing the same toxic intensity, as that for young rats at 1000 mg/kg, is considered to be slightly lower than 300 mg/kg, at 200–250 mg/kg/day. Therefore, pUETLs of 200–250 and 1000 mg/kg/day may be considered equivalent doses for newborn and young rats, respectively.

4-Chlorophenol (Table 2)

The newborn investigation was conducted at doses of 0, 20, 100, and 500 mg/kg for the dose-finding and 0, 12, 60, and 300 mg/kg for the main study. With young rats doses of 0, 20, 100, and 500 mg/kg were applied in both dose-finding and main studies.

Toxic effects on the CNS were observed in both sexes of newborn and young rats. Most newborn rats at 500 mg/kg in the dose-finding study showed tremors, hypoactivity, bradypnea and hypothermia, and died. All newborn rats at 300 mg/kg exhibited tremors, mostly within 15 minutes to one hour, but these completely disappeared within four hours after dosing. There were no abnormalities at 100 mg/kg in the dose-finding, and 60 and 12 mg/kg in the main study. No developmental abnormalities were observed at any dose in the newborn dose-finding and main studies. In the young study, tremors, tachypnea and salivation were observed from five to 30 minutes after dosing in most animals in both sexes at 500 mg/kg. There were no other dose-dependent changes at any dose.

The pNOAEL for newborn rats is considered to be 100 mg/kg/day, because CNS toxicity was not observed at 100 mg/kg in the dose-finding study. The pNOAEL for young rats must be set at 100 mg/kg/day, because there were no doses set between 100 and 500 mg/kg. Although the toxicity profile regarding the CNS differed to some extent between newborn rats at 300 mg/kg and young rats at 500 mg/kg with respect to symptom appearance and duration, the same level can be concluded, considering the specific characteristics of the newborn body. Thereby, pUETLs of 300 and 500 mg/kg/day were estimated as appropriate for newborn and young rats, respectively.

p-(α,α-Dimethylbenzyl) phenol (Table 3)

The newborn investigation was conducted at doses of 0, 30, 100, and 300 mg/kg for both dose-finding and main studies. The young investigation was conducted at doses of 0, 250, 500, and 1000 mg/kg for dose-finding and 0, 100, 300, and 1000 mg/kg for the main study.

No newborn animals died although the body weights of both sexes were transiently lowered at 300 mg/kg (8% maximum decrease). General behavior, functional parameters and urinalysis, hematology and biochemistry data were all within normal ranges except for high urinary volume in males and high BUN in females at 300 mg/kg. The relative kidney weights were increased more than double at 300 mg/kg in both sexes, and dilation of tubules and papillary ducts was observed at relatively high grades in kidneys of both sexes, with no complete recoveries even after a nine-week recovery-maintenance period. Such histopathological change in kidneys was also slightly observed at 100 mg/kg in both sexes. In addition, there were effects on the endocrine systems, despite no effects on sexual differentiation. Absolute testicular weights were reduced by 16% at 300 mg/kg and ovary weights by 26% at 100

Table 2 Toxicity findings for 4-chlorophenol in the newborn and young rat main studies

	Newborn study (mg/kg)				Young study (mg/kg)		
	0	60	100†	300	0	100	500
Male							
General behavior							
Tremors	0/12	0/12	0/4	12/12	0/12	0/6	12/12
Tachypnea	0/12	0/12	0/4	0/12	0/12	0/6	11/12
Salivation	0/12	0/12	0/4	0/12	0/12	0/6	9/12
Histopathology							
Kidney	0/6	0/6	no data	0/6	0/6	0/6	0/6
Liver	0/6	0/6	no data	0/6	0/6	0/6	0/6
Female							
General behavior							
Tremors	0/12	0/12	0/4	12/12	0/12	0/6	11/12
Tachypnea	0/12	0/12	0/4	0/12	0/12	0/6	9/12
Salivation	0/12	0/12	0/4	0/12	0/12	0/6	8/12
Histopathology							
Kidney	0/6	0/6	no data	0/6	0/6	0/6	0/6
Liver	0/6	0/6	no data	0/6	0/6	0/6	0/6

Data are numbers of animals with the change of the total examined. All newborn males and 3/4 females died at 500 mg/kg in the dose-finding study. †indicates dose and data from the dose-finding study.

Table 3 Major toxicity findings for p-(α,α-dimethylbenzyl) phenol in the newborn and young rat main studies

	Newborn study (mg/kg)				Young study (mg/kg)			
	0	30	100	300	0	100	300	1000
Male								
Dead or moribund	0/12	0/12	0/12	0/12	0/14	0/7	0/7	3/14
ALT, γ-GTP	/	–	–	–	/	–	–	↑
BUN, Creatinine	/	–	–	–	/	–	–	↑
Relative liver weight	/	–	–	–	/	–	↑	↑
Relative kidney weight	/	–	–	↑	/	–	–	↑
Stomach, hyperplasia	0/6	0/6	0/6	0/6	0/7	0/7	0/7	1/6
Liver, proliferation bile ducts	0/6	0/6	0/6	0/6	0/7	0/7	0/7	6/6
Kidney, regeneration	0/6	0/6	0/6	0/6	3/7	3/7	5/7	6/6
Kidney, dilatation	0/6	0/6	1/6	6/6	0/7	0/7	0/7	6/6
Female								
Dead or moribund	0/12	0/12	0/12	0/12	0/14	0/7	0/7	1/14
ALT, γ-GTP	/	–	–	–	/	–	–	↑
BUN, Creatinine	/	–	–	↑,–	/	–	–	–
Relative liver weight	/	–	–	–	/	–	–	↑
Relative kidney weight	/	–	–	↑	/	–	–	↑
Stomach, hyperplasia	0/6	0/6	0/6	0/6	0/7	0/7	0/7	3/7
Liver, proliferation bile ducts	0/6	0/6	0/6	0/6	0/7	0/7	0/7	7/7
Kidney, regeneration	0/6	0/6	0/6	0/6	0/7	1/7	0/7	7/7
Kidney, dilatation	0/6	0/6	2/6	6/6	0/7	0/7	0/7	4/7

Only critical data are shown in this table. Data are numbers of animals with the change of the number examined. Slashes and bars mean no statistical significance as compared to controls. ↑ indicates significant increase at $P < 0.05$. Relative kidney weights were increased 2.5- and 2.1-fold for males and females at 300 mg/kg in the newborn study. For the young study, 14 males and 14 females (half for examination of recovery) were assigned to each group but 6 males and 7 females at 1000 mg/kg were re-assigned for 28-day examination because of deaths.

and 300 mg/kg. The absolute ovary weights were still lowered by 32% at 300 mg/kg after the recovery-maintenance period. Increased numbers of atretic follicles were found in ovaries of half of the females at 300 mg/kg at the end of the dosing period, and most females continued to show various changes such as decreased numbers of corpa luteua in the ovaries and hypertrophy of endometrial epithelium in the uteri. after the recovery-maintenance period.

In the young study, two males and one female died, and one male was killed in a moribund condition at 1000 mg/kg. The final body weights were reduced by 18%, limited to males. On urinalysis, both sexes showed irregularly sized particles of a black substance, accompanied by 2–4 fold elevation of urine volume. Clear changes of several biochemical parameters such as ALT, γ-GTP, BUN, and creatinine, increases of relative liver and kidney weights, and histopathological changes in the forestomach (squamous hyperplasia), liver (bile duct proliferation), and kidney (regeneration of tubular epithelium and dilatation of tubules) were also observed at 1000 mg/kg. A dose of 300 mg/kg was considered to cause slight toxicity, because the abnormal urinary contents described above were found in half of both sexes and a slightly elevated incidence of mild regeneration of the tubular epithelium was noted in male kidneys. After the two-week recovery period, the pathological changes in male kidneys at 1000 mg/kg continued to be evident. There were no signs of toxicity at 250 and 500 mg/kg in the dose-finding study although the administration period was only half and urinalysis and histopathological examinations were not performed.

The pNOAEL of 30 mg/kg/day for newborn rats is clear and one of 100 mg/kg/day for young rats is reasonable because of slight toxicity at 300 mg/kg in the main study and limited information at 250 mg/kg in the dose-finding study. Toxicity for newborn rats was evident at 300 mg/kg as all animals of both sexes showed histopathological changes in kidneys, with increased relative weights. However, the degree of toxicity for young rats at 1000 mg/kg was obviously much stronger than that of newborn rats at 300 mg/kg, which appeared to be equivalent to doses of 700–800 mg/kg in young rats. Therefore, pUETLs of 300 and 700–800 mg/kg/day may be appropriate for newborn and young rats, respectively. It should be specially noted that this chemical may have endocrine disrupting properties, especially against females, when given only during the suckling phase.

(Hydroxyphenyl)methyl phenol (Table 4)

The newborn investigation was conducted at doses of 0, 20, 60, and 200 mg/kg for dose-finding and 0, 16, 40, and 100 mg/kg for the main study. The young study was conducted at doses of 0, 100, 500, and 1000 mg/kg for dose-finding and 0, 8, 40, 200, and 1000 mg/kg for the main study.

Common changes were limited to depression of body weight and death at high doses in newborn and young rats. The highest dose of 100 mg/kg in the newborn main study did not cause any changes, but half the animals at 200 mg/kg in the newborn dose-finding study died, without accompanying liver weight changes in surviving

Table 4 Major toxicity findings for (hydroxyphenyl)methyl phenol in the newborn and young rat main studies

	Newborn study (mg/kg)			Young study (mg/kg)			
	0	100	200†	0	40	200	1000
Male							
Dead or moribund	0/12	0/12	3/6	0/12	0/12	0/12	0/12
Final body weight	/	–	↓	/	–	–	↓
Total cholesterol	/	–	↑	/	–	–	↓
Relative liver weight	/	–	–	/	–	–	↑
Stomach, hyperplasia	0/6	0/6	no data	0/6	0/6	0/6	6/6
Liver, centrilobular hypertrophy	0/6	0/6	no data	0/6	0/6	2/6	4/6
Female							
Dead or moribund	0/12	0/12	3/6	0/12	0/12	0/12	1/12
Final body weight	/	–	(↓)	/	–	–	(↓)
Total cholesterol	/	–	–	/	↓	↓	↓
Relative liver weight	/	–	–	/	–	↑	↑
Stomach, hyperplasia	0/6	0/6	no data	0/6	0/6	0/6	6/6
Liver, centrilobular hypertrophy	0/6	0/6	no data	0/6	0/6	0/6	4/6

Only critical data are shown in this table. † indicates a dose from the dose-finding study. Numbers are for animals with the feature in the total examined. Slashes and bars mean no statistical significance as compared with controls. ↑ indicates significant increase $P < 0.05$. ↓indicates significant decrease at $P < 0.05$. () indicates that statistical significance was not obtained. Final body weights of surviving newborn males at 200 mg/kg in the dose-finding study were reduced by 30% (14% for females, not significant), respectively. Final body weights of young male rats at 1000 mg/kg in the main study were decreased by 11.8% (5.7% for females, not significant). Increase of relative liver weights was 13% in females at 200 mg/kg, and 16 and 27% in males and females at 1000 mg/kg in the young main study.

animals. There were no chemical-related changes with other examinations, including developmental parameters. In the young study, one female became moribund and the final body weights of males were decreased at 1000 mg/kg. All animals of both sexes at this dose showed squamous hyperplasia of the forestomach or limiting ridge with ulceration, and two-thirds of the animals featured centrilobular hypertrophy of hepatocytes with decrease of total cholesterol (29–51% drop) and increase of relative liver weight. At 200 mg/kg, low incidences of centrilobular hypertrophy in the livers of males and slight increase of liver weights in females with low total cholesterol (45% drop) were found. No toxicity was apparent at 40 mg/kg in the main study. No toxicity was also found at 100 mg/kg in the dose-finding study, but a histopathological examination was not conducted. There were no abnormalities on hematological examination and urinalysis at any dose.

The pNOAEL is considered to be 100 mg/kg/day for newborn rats and 40 mg/kg/day may be appropriate for young rats because of the limited information at 100 mg/kg in the dose-finding study. Although toxicity at 1000 mg/kg for young rats was evident, the dose inducing the same effects in newborn rats was clearly less than 200 mg/kg, because half of the animals died at this dose. We speculate that the dose range for one death in 12 newborn rats would be within 140–160 mg/kg. It is clear that the dose–response curve is much steeper for newborn than young rats. Based on our consideration, pUETLs of 140–160 and 1000 mg/kg/day may be equivalent for newborn and young rats, respectively.

Trityl chloride (Table 5)

The newborn investigation was conducted at doses of 0, 20, 60, 200, and 600 mg/kg for dose-finding and 0, 12, 60, and 300 mg/kg for the main study. The young investigation was conducted at doses of 0, 30, 100, 300, and 1000 mg/kg for dose-finding and 0, 12, 60, and 300 mg/kg for the main study.

Common effects were observed in livers of newborn and young rats. In the newborn study, increase of relative liver weights were shown at 60 mg/kg and more in both sexes and centrilobular hypertrophy of hepatocytes was noted in 300 mg/kg females. In the dose-finding newborn study, one female died and increase of relative liver weights of both sexes at 600 mg/kg was more evident with low body weights (11.3% drop for males, 13.8% for females). There were no chemical-related changes with other examinations, including developmental parameters. In the young study, both sexes at 60 mg/kg showed a high incidence of centrilobular hypertrophy of hypetocytes with limited increases of relative liver weights (10–14%). At 300 mg/kg, soft feces and mucosal thickening of cecum in most animals were observed in addition to more extensive hepatic changes. Although relative kidney weights were increased at 300 mg/kg in males and 60 and 300 mg/kg in females, there were no renal histopathological findings. Hematological and blood chemical examinations revealed several slight to moderate changes (56% as the maximum) in fibrinogen, ALT, total cholesterol and glucose, as well as prolongation of prothrombin and activated thromboplastin times, at 300 mg/kg.

pNOAELs of 60 and 12 mg/kg/day for newborn and young rats appear appropriate because of the lack of information at higher doses in the dose-finding study, which showed no toxicity but without histopathological examination. The dose of 300 mg/kg in the young main study was a clear toxic level, but intensity was much stronger than that at 300 mg/kg in the newborn main study, while less that at 600 mg/kg in the dose-finding study. Based on these data, the toxicity with 300 mg/kg for young rats is considered to be within the range with 400–500 mg/kg for newborn rats.

Table 5 Major toxicity findings for trityl chloride in the newborn and young rat main studies

	Newborn study (mg/kg)				Young study (mg/kg)			
	0	60	300	600†	0	12	60	300
Male								
Death	0/12	0/12	0/12	0/6	0/12	0/6	0/12	0/12
Final body weight	/	–	–	↓	/	–	–	↓
ALT, Total cholesterol	/	–	–	–	/	–	–	↑
Relative liver weight	/	↑	↑	↑	–	–	↑	↑
Relative kidney weight	/	–	–	–	–	–	–	↑
Cecum, thickening	0/6	0/6	0/6	no data	0/6	0/6	0/6	5/6
Liver, centrilobular hypertrophy	0/6	0/6	0/6	no data	0/6	0/6	3/6	6/6
Female								
Death	0/12	0/12	0/12	1/6	0/12	0/6	0/12	0/12
Final body weight	/	–	–	↓	/	–	–	–
ALT, Total cholesterol	/	–	–	–	/	–	–	-,↑
Relative liver weight	/	↑	↑	↑	–	–	↑	↑
Relative kidney weight	/	–	–	–	–	–	↑	↑
Cecum, thickening	0/6	0/6	0/6	no data	0/6	0/6	2/6	5/6
Liver, centrilobular hypertrophy	0/6	0/6	4/6	no data	0/6	0/6	5/6	6/6

Only critical data are shown in this table. †indicates a dose from the dose-finding study. Numbers are for animals with the feature in the total examined. Slashes and bars mean no statistical significance as compared to controls. ↑ indicates significant increase $P < 0.05$. ↓indicates significant decrease at $P < 0.05$. Relative liver weights were increased by 11% for males and 8% for females at 60 mg/kg, and 29% for both sexes at 300 mg/kg in the newborn main study and by 44% for males and 46% for females at 600 mg/kg in the newborn dose-finding study. Body weight depression in males (13%) and an increase of relative liver weights (32% for males, 40% for females) were observed at 300 mg/kg in the young main study.

Therefore, pUETLs of 400–500 and 300 mg/kg/day are proposed as appropriate for newborn and young rats, respectively.

1,3,5-Trihydroxybenzene (Table 6)

The newborn investigation was conducted at doses of 0, 100, 500, and 1000 mg/kg for dose-finding and at 0, 20, 100, and 500 mg/kg for the main study. The young investigation was conducted at doses of 0, 100, 250, 500, and 1000 mg/kg for dose-finding and at 0, 30, 100, 300, and 1000 mg/kg for the main study.

Common changes were observed in the thyroids and liver. The only toxic change in newborn main study was hypertrophy of thyroid follicular cells with increase in relative thyroid weights in both sexes at 500 mg/kg. Increased relative liver weights in females were not accompanied by any histopathological changes. Although decrease of adrenal weight and histopathological alterations such as vacuolization and pigmentation were noted at the end of the dosing and recovery-maintenance periods, these were always slight and not dose-dependent. There were no chemical-related changes with other examinations, including developmental parameters, in newborn rats. In the young study, similar effects on the thyroids and liver were found at 1000 mg/kg, but the incidence of thyroid histopathological changes was slightly less than in newborn animals at 500 mg/kg.

pNOAELs of 100 and 300 mg/kg/day for newborn and young rats can be considered appropriate because of the lack of data with dose settings between 100 to 500 mg/kg in the newborn, and no histopathological examination at 500 mg/kg in the young dose-finding study. The degree of toxicity at 1000 mg/kg for young rats was almost equal to that at 500 mg/kg for newborn rats. Therefore, pUETLs of 500 and 1000 mg/kg/day are proposed as equivalents for newborn and young rats, respectively.

DISCUSSION

More than 100 000 industrial chemicals are now in use around the world and sufficient toxicity information is available for only a small proportion. The Japanese government started the Existing Chemical Safety Program to obtain minimal toxicity data sets from 28-day toxicity studies using young rats for high production volume chemicals lacking toxicity information. For the present six targeted chemicals, we found toxicity information for only two chemicals by literature search. Daniel *et al.* (1993) reported no toxic effects of 2-chlorophenol on oral administration to male and female Sprague Dawley rats at up to 257 mg/kg for 10 days or 150 mg/kg for 90 days. Our results were consistent with their data, as we found no toxicity at 500 mg/kg in young dose-finding study (14 days administration) and at 200 mg/kg in the young study (28 days), while further providing information on CNS effects at higher doses. As for (hydroxyphenyl)methyl phenol, consisting of bisphenol D, E, and F isomers, bisphenol F has been reported to have estrogenic potential evidenced by several *in vitro* and *in vivo* experiments (Hashimoto *et al.* 2001; Yamasaki *et al.* 2002; Stroheker *et al.* 2003). However, we could not establish any such activity in this study. Our results are reasonable because oral administration of bisphenol F increased relative uterus weights only at more than 100 mg/kg, but not 50 mg/kg given during PNDs 22–25 (Stroheker *et al.* 2003), while our highest dose of (hydroxyphenyl)methyl phenol was equivalent to 30 mg/kg of bisphenol F.

Table 6 Major toxicity findings for 1,3,5-trihydroxybenzene in the newborn and young rat main studies

	Newborn study (mg/kg)			Young study (mg/kg)		
	0	100	500	0	300	1000
Male						
Relative organ weight						
Liver	/	–	–	/	–	↑
Thyroids	/	–	↑	/	–	(↑)
Histopathology						
Liver	0/6	0/6	0/6	0/6	0/6	0/6
Thyroids, hypertrophy	0/6	0/6	4/6	0/6	0/6	2/6
Female						
Relative organ weight						
Liver	/	–	↑	/	–	↑
Thyroids	/	–	(↑)	/	–	(↑)
Histopathology						
Liver	0/6	0/6	0/6	0/6	0/6	0/6
Thyroids, hypertrophy	0/6	0/6	5/6	0/6	0/6	4/6

Only critical data are shown in this table. Slashes and bars mean no statistical significance as compared with controls. ↑ indicates significant increase $P < 0.05$ (except in parentheses where statistical significance was not attained). Numbers are for animals with the feature in the total examined. Increase of relative organ weights at 500 mg/kg in the newborn main study was observed for thyroids (39% for males, 24% for females) and liver (9% for females). Increase of relative organ weights at 1000 mg/kg in the young main study was observed for thyroids (14% for males, 19% for females) and liver (23% for males and 9% for females).

Table 7 Comparative susceptibility of newborn and young rats to the six chemicals

	Newborn study		Young study		pNOAEL	pUETL
	pNOAEL	pUETL	pNOAEL	pUETL	Young/Newborn	Young/Newborn
	mg/kg/day		mg/kg/day			
2-Chlorophenol	40	200–250	200	1000	5.0	4.0–5.0
4-Chlorophenol	100	300	100	500	1.0	1.7
p-(α,α-Dimethylbenzyl) phenol	30	300	100	700–800	3.3	2.3–2.7
(Hydroxyphenyl) methyl phenol	100	140–160	40	1000	0.4	6.3–7.1
Trityl chloride	60	400–500	12	300	0.2	0.6–0.8
1,3,5-Trihydroxybenzene	100	500	300	1000	3.0	2.0

Although there has been no reports for p-(α,α-dimethylbenzyl) phenol, it causes endocrine disruption and possible antiestrogenic activity, when administered to newborn female rats in this study. Therefore, further studies on this chemical should be conducted to elucidate the mechanisms, because the present investigation did not indicate any effects on sexual differentiation such as preputial separation, vaginal opening and the estrous cycle.

For our focus on the comparative sensitivity of newborn and young rats to chemicals, two toxicity endpoints, pNOAEL and pUETL, were newly defined as appropriate, considering the entire data sets from both main and dose-finding studies. We believe that this alternative assessment approach allowed us to make more realistic comparisons between newborn and young rats under the same experimental conditions as far as possible.

The ratios of pNOAELs for chemicals between newborn and young rats may provide an additional UF value in risk assessment according to susceptibility of newborn rats, because regulatory limit values for chemicals to protect public health of humans, including infants, are derived from the division of NOAEL by UFs. The data in Table 7 indicate newborn rats to be 1–5 times more susceptible to four of the tested chemicals, 2- and 4-chlorophenols, p-(α,α-dimethylbenzyl) phenol and 1,3,5-trihydroxybenzene, than young rats in terms of the pNOAELs, similar to the results of previous analyzes of five phenolic chemicals, 4-nitro-, 2,4-dinitro-, 2,4,6-trinitro-, 3-methyl- and 3-amino-phenols (Koizumi *et al.* 2001, 2002, 2003; Takahashi *et al.* 2004). Immaturity in the detoxification potential of phase 1 and phase 2 enzymes in newborn animals may be the major cause of higher toxicity in newborn rats (Rich & Boobis 1997; Gow *et al.* 2001), because these chemical classes are probably direct toxicants. In the case of (hydroxyphenyl)methyl phenol, the pNOAEL (100 mg/kg/day) for newborn rats was 2.5 times higher than that (40 mg/kg/day) for young rats, but it can be speculated that values are in practice rather similar because the toxicity for young rats at the high dose, 200 mg/kg, was only slight (Table 4). As for trityl chloride, newborn rats were obviously less susceptible (0.2 for the pNOAEL ratio). Similar results were

also reported from our previous analysis for bromoalkanes (Hirata-Koizumi *et al.* 2005) and may be explained by mechanisms of action and metabolic characteristics of newborn rats. As this class of chemicals possibly requires metabolism to act as toxicants, the relatively mature metabolic enzyme status of young rats would be expected to provide toxic intermediates by metabolic activation to a greater extent than in newborn rats, as evidenced by data for previously reported chemicals (Onkenhout *et al.* 1986; Kennedy *et al.* 1993). Other compounds such as acetaminophen, bromobenzene, and carbon tetrachloride have also been shown to not produce liver injury in neonatal animals at doses that are hepatotoxic to adults (Gregus & Klaassen 1998).

The ratios of pUETLs, doses inducing the same degree of toxicity in newborn and young rats, were almost the same as for pNOAELs with the direct toxicants, as shown in Table 7. However, newborn rats were considerably more susceptible to (hydroxyphenyl)methyl phenol when considering the pUETL, due to the much steeper dose–response curve in newborn rats, with a 100 mg/kg/day pNOAEL and half the animals dying at 200 mg/kg, compared with a 40 mg/kg/day pNOAEL and only one death in 12 animals at 1000 mg/kg for young rats. Although young rats showed stomach hyperplasia in addition to hepatotoxicity at 1000 mg/kg, the cause of newborn deaths at 200 mg/kg was unclear. With regard to trityl chloride, the pUETL for young rats was almost the same as for newborn although the latter were less susceptible. Such an anomaly has also been found for bromoalkanes previously analyzed. Another example of a chemical for which susceptibility differs at low and high doses is chlorpyrifos, the maximum tolerated dose in 17-day-old rats being reported to be five times less than that in adults following oral exposure (Moser & Padilla 1998), but the differential sensitivity not appearing in low-dose exposure (Pope & Liu 1997). Thus as there are several chemicals of which dose–response curve in newborn rats was obviously steeper than that in young rats, pUETL ratios should be also taken into account for the susceptibility of newborn rats as the second endpoint marker.

In conclusion, newborn rats were 2–5 times more susceptible than young rats in terms of both the pNOAEL and the pUETL in most cases. One exception was that young rats were clearly more susceptible than their newborn counterparts for trityl chloride.

ACKNOWLEDGMENT

The authors gratefully acknowledge the financial support of the Office of Chemical Safety, Pharmaceutical and Medical Safety Bureau, Ministry of Health, Labor and Welfare, Japan and also deeply appreciate the efforts of the six Japanese contract laboratories in performing the actual animal toxicity studies.

REFERENCES

Bartlett MS (1937) Properties of sufficiency and statistical tests. *P Roy Soc Lond A Mat* **160**: 268–282.

Chemical Products' Handbook (2004) *Chemical Products of 14504 '14504 no Kagakushohin'*. The Chemical Daily, Tokyo (in Japanese).

Daniel FB, Robinson M, Olson GR, York RG, Condie LW (1993) Ten and ninety-day toxicity studies of 2-chlorophenol in Sprague-Dawley rats. *Drug Chem Toxicol* **16**: 277–291.

Dourson M, Charnley G, Scheuplein R (2002) Differential sensitivity of children and adults to chemical toxicity. II. Risk and regulation. *Regul Toxicol Pharmacol* **35**: 448–467.

Dunnett CW (1964) New tables for multiple comparisons with a control. *Biometrics* **20**: 482–491.

Fisher RA (1973) *Statistical Methods for Research Workers*, 14th edn. Hafner Publishing Co, New York.

Fukuda N, Ito Y, Yamaguchi M *et al.* (2004) Unexpected nephrotoxicity induced by tetrabromobisphenol A in newborn rats. *Toxicol Lett* **150**: 145–155.

Gow PJ, Ghabrial H, Smallwood RA, Morgan DJ, Ching MS (2001) Neonatal hepatic drug elimination. *Pharmacol Toxicol* **88**: 3–15.

Gregus Z, Klaassen CD (1998) Hepatic disposition of xenobiotics during prenatal and postnatal development. In: Polin RA, Fox WF, (eds). *Fetal and Neonatal Physiology*. Saunders, Philadelphia, pp. 1472–1493.

Hasegawa R, Koizumi M, Hirose A (2004) Principles of risk assessment for determining the safety of chemicals: Recent assessment of residual solvents in drugs and di (2-ethylhexyl) phthalate. *Congenit Anom Kyoto* **44**: 51–59.

Hashimoto Y, Moriguchi Y, Oshima H, Kawaguchi M, Miyazaki K, Nakamura M (2001) Measurement of estrogenic activity of chemicals for the development of new dental polymers. *Toxicol In Vitro* **15**: 421–425.

Hirata-Koizumi M, Kusuoka O, Nishimura N *et al.* (2005) Susceptibility of newborn rats to hepatotoxicity of 1,3-dibromopropane and 1,1,2,2-tetrabromomethane, compared with young rats. *J Toxicol Sci* **30**: 29–42.

Hollander M, Wolfe DA (1973) *Nonparametric Statistical Methods*. John Wiley and Sons, New York.

IPCS (International Programme on Chemical Safety) (2002) *Global Assessment of the State-of-the-Science of Endocrine Disruptors*. Damstra T, Barlow S, Bergman A, Kavlock R, van der Kraak G (eds). World Health Organization, Geneva.

Kennedy CH, Cohen KB, Bechtold WE *et al.* (1993) Effect of dose on the metabolism of 1,1,2,2-tetrabromoethane in F344/N rats after gavage administration. *Toxicol Appl Pharmacol* **119**: 23–33.

Koizumi M, Nishimura N, Enami T *et al.* (2002) Comparative toxicity study of 3-aminophenol in newborn and young rats. *J Toxicol Sci* **27**: 411–421.

Koizumi M, Noda A, Ito Y *et al.* (2003) Higher susceptibility of newborn than young rats to 3-methylphenol. *J Toxicol Sci* **28**: 59–70.

Koizumi M, Yamamoto Y, Ito Y *et al.* (2001) Comparative study of the toxicity of 4-nitrophenol and 2,4-dinitrophenol in newborn and young rats. *J Toxicol Sci* **26**: 299–311.

Landrigan PJ, Kimmel CA, Correa A, Eskenazi B (2004) Children's health and the environment: Public health issues and challenges for risk assessment. *Environ Health Perspect* **112**: 257–265.

Lee PC (1998) Disruption of male reproductive tract development by administration of the xenoestrogen, nonylphenol, to male newborn rats. *Endocrine* **9**: 105–111.

Mann HB, Whitney DR (1947) On a test of whether one of two random variables is stochastically larger than the other. *Ann Math Stat* **18**: 50–60.

Moser VC, Padilla S (1998) Age- and gender-related differences in the time course of behavioral and biochemical effects produced by oral chlorpyrifos in rats. *Toxicol Appl Pharmacol* **149**: 107–119.

Onkenhout W, Van Bergen EJ, Van der Wart JH, Vos GP, Buijs W, Vermeulen NP (1986) Identification and quantitative determination of four different mercapturic acids formed from 1,3-dibromopropane and its 1,1,3,3-tetradeutero analogue by the rat. *Xenobiotica* **16**: 21–33.

Pope CN, Liu J (1997) Age-related differences in sensitivity to organophosphorus pesticides. *Environ Toxicol Pharmacol* **4**: 309–314.

Rich KJ, Boobis AR (1997) Expression and inducibility of P450 enzymes during liver ontogeny. *Microsc Res Tech* **39**: 424–435.

Steel RD (1959) A multiple comparison rank sum test: Treatment versus control. *Biometrics* **15**: 560–572.

Stroheker T, Chagnon MC, Pinnert MF, Berges R, Canivenc-Lavier MC (2003) Estrogenic effects of food wrap packaging xenoestrogens and flavonoids in female Wistar rats: A comparative study. *Reprod Toxicol* **17**: 421–432.

Takahashi M, Ogata H, Izumi H *et al.* (2004) Comparative study of toxicity of 2,4,6-trinitrophenol (picric acid) in newborn and young rats. *Congenit Anom Kyoto* **44**: 204–214.

Takahashi O, Oishi S (2001) Testicular toxicity of dietary 2,2-bis (4-hydroxyphenyl) propane (bisphenol A) in F344 rats. *Arch Toxicol* **75**: 42–51.

Yamasaki K, Takeyoshi M, Yakabe Y *et al.* (2002) Comparison of reporter gene assay and immature rat uterotrophic assay of twenty-three chemicals. *Toxicology* **170**: 21–30.

Congenital Anomalies 2005; 45, 146–153

ORIGINAL ARTICLE

Elevated susceptibility of newborn as compared with young rats to 2-*tert*-butylphenol and 2,4-di-*tert*-butylphenol toxicity

Mutsuko Hirata-Koizumi[1], Masao Hamamura[2], Hiromi Furukawa[2], Naemi Fukuda[3], Yoshihiko Ito[3], Yumi Wako[4], Kotaro Yamashita[4], Mika Takahashi[1], Eiichi Kamata[1], Makoto Ema[1], and Ryuichi Hasegawa[1]

[1]National Institute of Health Sciences, Setagaya-ku, Tokyo; [2]Panapharm Laboratories, Uto-shi, Kumamoto; [3]Research Institute for Animal Science in Biochemistry and Toxicology, Sagamihara-shi, Kanagawa; and [4]Kashima Laboratory, Mitsubishi Chemical Safety Institute Ltd, Ibaraki, Japan

ABSTRACT **In order to determine the susceptibility of newborn rats to 2-*tert*-butylphenol (2TBP) and 2,4-di-*tert*-butylphenol (DTBP) toxicity, studies were conducted with oral administration from postnatal days (PND) 4 to 21 and the findings were compared with results for young rats exposed from 5 or 6 weeks of age for 28 days. In the newborn rats, specific effects on physical and sexual development and reflex ontogeny were not observed. While there were no clear differences in toxicological profiles between newborn and young rats, the no-observed-adverse-effect levels (NOAELs) differed markedly. For 2TBP, clinical signs such as ataxic gait, decrease in locomotor activity and effects on liver, such as increase in organ weight, were observed and the NOAELs were concluded to be 20 and 100 mg/kg/day in newborn and young rats, respectively. Based on hepatic and renal toxicity (histopathological changes and increase in organ weight with blood biochemical changes), the respective NOAELs for DTBP were concluded to be 5 and 20 mg/kg/day. Therefore, the susceptibility of newborn rats to 2TBP and DTBP was found to be 4–5 times higher than that of young rats.**

Key Words: 2, 4-di-*tert*-butylphenol, 2-*tert*-butylphenol, susceptibility of newborn rats

INTRODUCTION

Protection of humans against disease and injury caused by chemicals in the environment is the ultimate goal of risk assessment and risk management (Landrigan *et al.* 2004). However, the focus has long been solely on adult exposure and toxicity and the fetus via maternal transfer, with little consideration given to early childhood. In the past decade, stimulated especially by the 1993 US National Research Council (NRC) report *Pesticides in the Diets of Infants and Children* (NAS 1993), recognition that special consideration is required for children in risk assessment has grown. The NRC report noted that 'children are not little adults', because of their unique patterns of exposures to environmental hazards and their particular vulnerability.

For the susceptibility of children to environmental chemicals, the early postnatal period (the suckling period) is of particular note. During this period, the infant could be exposed to various chemicals not only through mothers' milk, but also directly, by having chemical-contaminated baby food, mouthing toys or household materials, and so on; however, current risk assessment gives no consideration to toxic effects resulting from direct exposure to chemicals. An approach that adequately takes into account the susceptibility of infancy is urgently required. However, because there is no standard testing protocol intended for direct exposure of preweaning animals (newborn animals) to chemicals, and toxicity studies using newborn animals are complicated by practical difficulties regarding grouping, direct dosing, and general and functional observation, there is only limited information on susceptibility of the newborn at the present.

We therefore have established a new protocol for repeated dose toxicity studies using newborn rats (newborn rat studies) (Koizumi *et al.* 2001) for systematic application. Results have been compared with those of 28-day repeated dose toxicity studies using young rats (young rat studies) to provide a basis of analyzing susceptibility. Since young rat studies are routinely conducted as one of a battery of minimum toxicity tests and data are stored for many chemicals, comparative analyzes should provide important information for considering effects of direct exposure to chemicals during the suckling period.

We have already reported analytical results for eight chemicals (4-nitrophenol, 2,4-dinitrophenol, 3-aminophenol, 3-methylphenol, 1,3-dibromopropane, 1,1,2,2-tetrabromoethane, 2,4,6-trinitrophenol, and tetrabromobisphenol A) (Koizumi *et al.* 2001, 2002, 2003; Fukuda *et al.* 2004; Takahashi *et al.* 2004; Hirata-Koizumi *et al.* 2005). The susceptibility of newborn rats to the toxicity of the first four agents was four times higher than that of their young counterparts at a maximum. For 1,3-dibromopropane and 1,1,2,2-tetrabromoethane, while the doses causing clear toxicity were lower in newborn rats, doses at which toxic signs began to appear were paradoxically higher in the newborn case. These six chemicals had no impact on development in the newborn period and showed similar toxicity profiles in both age groups. For the other two chemicals, there were marked differences in toxicity profile between the newborn and young rats. Especially, in the case of tetrabromobisphenol A, a specific rather than enhanced renal toxicity was observed in newborn case.

In the present investigation, two *tert*-butylphenols, 2-*tert*-butylphenol (2TBP), and 2,4-di-*tert*-butylphenol (DTBP), were chosen for comparative toxicity analysis. 2TBP has been used in the production of agricultural chemicals, aroma chemicals, and resins (New Chemical Index 2001), and DTBP in the production of antioxidants and ultraviolet absorbers (Chemical Products' Handbook 2004). For either chemical, there is no available toxicity information on human. Regarding toxicity to experimental animals, results from young rat studies of both chemicals are available in

Correspondence: Mutsuko Hirata-Koizumi, BSc, Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan. Email: mkoizumi@nihs.go.jp

Received June 17, 2005; revised and accepted September 2, 2005.

Toxicity Testing Reports of Environmental Chemicals of the Japanese government (MHLW 2001a, 2001b), but no other data have been reported regarding repeated dose toxicity. Since the young rats were only evaluated for toxicity profiles and no-observed-effect levels, we re-evaluated the results for a more practical evaluation index, the no-observed-adverse-effect level (NOAEL), which could serve as the basis for determining tolerable daily intake (TDI) or acceptable daily intake (ADI) for risk assessment, and conducted comparative analyzes with newborn rats.

MATERIALS

2-*tert*-Butylphenol (2TBP, CAS no. 88-18-6, purity: 99.97%) and 2,4-di-*tert*-butylphenol (DTBP, CAS no. 96-76-4, purity: 99.67%), obtained from Dainippon Ink and Chemicals, Incorporated (Tokyo, Japan), were dissolved in olive oil and corn oil, respectively. The test solutions were prepared once a week as stability for eight days had been confirmed. All other reagents used in this study were specific purity grade.

METHODS

All studies were performed under Good Laboratory Practice conditions and in accordance with 'Guidance for Animal Care and Use' of Panapharm Laboratories Co., Ltd, Research Institute for Animal Science in Biochemistry and Toxicology, or Mitsubishi Chemical Safety Institute Ltd.

Animals

In the newborn rat studies of 2TBP and DTBP, pregnant SPF Sprague-Dawley rats [Crj:CD(SD)IGS] were purchased at gestation days 13–15 from Charles River Japan Inc. (Yokohama, Japan), and allowed to deliver spontaneously. All newborn were separated from dams at postnatal day (PND) 3 (the date of birth was defined as PND 0), and pooled according to sex. At the same time, 12 foster mothers were selected among dams, based on the nursing condition. Each foster mother suckled four male and four female newborn, assigned to each of the four dose groups, including the controls, up to weaning on PND 21 (termination of dosing). After weaning, the animals of the recovery-maintenance group (see Study Design) were individually maintained for nine weeks.

In the young rat studies, 4–5 week-old males and females of the same strain were obtained from the same supplier as for the newborn rat studies, and used at ages of 5–6 weeks after acclimation.

All animals were maintained in an environmentally controlled room at 20–26°C with a relative humidity of 40–70%, a ventilation rate of more than ten times per hour, and a 12:12 h light/dark cycle. They were allowed free access to a basal diet (MF: Oriental Yeast Co. Ltd, Tokyo, Japan, or LABO MR Stock: Nihon Nosan Kogyo Inc., Yokohama, Japan) and water (sterile tap water or well water treated with sodium hypochlorite) throughout.

Study design

1. 18-day repeated dose toxicity study in newborn rats (newborn rat study)

Newborn rats (12/sex/dose) were administered the test substances by gastric intubation on PNDs 4–21. On PND 22, six males and six females in each treated group were sacrificed for autopsy (the scheduled-sacrifice group). The remaining animals in all groups (6 rats/sex/dose) were maintained for nine weeks without chemical treatment and then sacrificed at 12 weeks of age (the recovery-maintenance group).

Based on the results of dose-finding studies conducted prior to the main study, the dose, which would show clear toxicity, was selected as the top dose, that without potentially toxic effects as the lowest dose, and the medium dose was set between them. In the dose-finding study for 2TBP (oral administration from PNDs 4–21), some clinical signs and suppressed body weight gain were observed at 200 mg/kg and an increase in relative liver weight at 60 mg/kg and more. For DBTP (oral administration from PNDs 4–17), all of the four males and four females died at 500 mg/kg, and the death of one of the four males, an increase in serum total cholesterol and phospholipid, and increase in relative liver weight were noted in the 100 mg/kg group. Therefore, the doses were set at 0, 20, 60, or 200 mg/kg/day for 2TBP and at 0, 5, 40, or 300 mg/kg/day for DTBP.

During the study, the rats' general condition was observed at least once a day (details of clinical signs noted in this study are described in 'Glossary of terms for toxicity testing' [NIHS 1994]). Body weight and food consumption (only the recovery-maintenance period) was examined once or more a week. As developmental parameters, fur appearance, incisor eruption, pinna detachment and eye opening were assessed for physical development, and testes descent or preputial separation and vaginal opening for sexual development (OECD 2004). In addition, reflex ontogeny, such as visual placing reflex, and surface and mid-air righting reflexes, were also examined (Adams 1986; Jensh & Brent 1988). Urinalysis (color, occult blood, pH, protein, glucose, ketone bodies, bilirubin, urobilinogen, sediment, specific gravity, and volume of the urine) was conducted in the last week of the recovery-maintenance period.

At PNDs 22 and 85, blood was collected from the abdominal aorta under ether anesthesia (for 2TBP) or from the postcaval vein under pentobarbital sodium anesthesia (for DTBP) after overnight starvation for the scheduled-sacrifice and recovery-maintenance groups, respectively. One portion was treated with EDTA-2K and examined for hematological parameters, such as the red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, white blood cell count, platelet count, reticulocyte count and differential leukocyte count. In the recovery-maintenance group, part of the blood was treated with 3.8% sodium citrate, and blood clotting parameters such as prothrombin time (PT) and activated partial thromboplastin time (APTT) were examined. Serum from the remaining portions of blood for both the scheduled-sacrifice and recovery-maintenance groups were analyzed for blood biochemistry (total protein, albumin, albumin-globulin ratio [A/G ratio], glucose, total cholesterol, triglycerides, phospholipid, total bilirubin, urea nitrogen [BUN], creatinine, glutamate oxaloacetate transaminase, glutamate pyruvate transaminase, alkaline phosphatase, -glutamyl transpeptidase [-GTP], calcium, inorganic phosphorus, sodium, potassium, and chlorine). Following collection of blood, all animals were sacrificed by exsanguination, and all organs and tissues were macroscopically examined. Then, the brain, pituitary gland, thymus, thyroids, heart, lungs, liver, spleen, kidneys, adrenals, testes, epididymides, and ovaries were removed and weighed. Histopathological examination was conducted for the control and the highest dose groups. The above-listed organs were fixed in 10% buffered formalin-phosphate (following Bouin's fixation for testes and epididymides), and paraffin sections were routinely prepared and stained with Hematoxylin-Eosin for microscopy. For other groups, organs with macroscopically abnormal findings or in which chemical-related effects were evident on microscopic examination for the highest dose group, were similarly investigated.

2. 28-day repeated dose toxicity study in young rats (young rat study)

Five to six week old rats were given the test substances by gastric intubation daily for 28 days and sacrificed following the last treatment (the scheduled-sacrifice group). Recovery groups were maintained for two weeks without chemical treatment and sacrificed at 11 or 12 weeks of age. The number of animals was six for each sex/dose for both scheduled-sacrificed and recovery cases.

The doses were selected in the same way as the newborn rat studies. In the 12-day dose-finding study for 2TBP, ataxic gait was observed at 300 mg/kg and more, and increase in relative liver and kidney weight at 500 mg/kg. For DTBP, with 14-day administration, the death of one of the four females, various changes in some blood biochemical parameters, increase in relative liver weights and light gray macules on kidneys were found at 500 mg/kg. Increase in serum phospholipid and relative liver weights were also demonstrated in the 100 mg/kg group. Based on the results, the doses were determined at 0, 4, 20, 100, or 500 mg/kg/day for 2TBP and at 0, 5, 20, 75, or 300 mg/kg/day for DTBP. Recovery groups were set at 0, 100, 500 mg/kg/day for 2TBP and 0, 300 mg/kg/day for DTBP.

During the study, rats were examined for general condition, body weight, food consumption, urinalysis, hematology and blood biochemistry, necropsy findings, organ weights, and histopathological findings in compliance with the Test Guideline in the Japanese Chemical Control Act (Official Name: Law Concerning the Examination and Regulation of Manufacture, etc. of Chemical Substances).

Statistical analysis

Data for body weights, food consumption, urinalysis findings (except for the results of qualitative analysis), hematological, blood biochemical findings (except for differential leukocyte count), and organ weights were analyzed by the Bartlett's test (Bartlett 1937) for homogeneity of distribution. When homogeneity was recognized, Dunnett's test (Dunnett 1964) was conducted for comparison between control and individual treatment groups ($P < 0.01$ or 0.05). If not homogeneous or for qualitative urinalysis data and differential leukocyte count, the data were analyzed using Steel's multiple comparison tests (Steel 1959), or tests of the Dunnett type (Hollander & Wolfe 1973) ($P < 0.01$ or 0.05). For reflex ontogeny, and physical and sexual development parameters in the newborn rat studies, the ^{2}-test (Fisher 1922) was conducted ($P < 0.01$ or 0.05).

RESULTS

2-*tert*-butylphenol (2TBP)

Newborn rat study

Various clinical signs such as decrease in locomotor activity, ataxic gait, deep respiration, and muscle weakness were observed throughout the dosing period in the 200 mg/kg group, as shown in Table 1. With 60 mg/kg, transient decrease in locomotor activity was noted on the first dosing day limited to only one of 12 males. Body weights were lowered by 8–17% from dosing day 7 through to the end of the dosing period in males and to recovery-maintenance day 14 in females given 200 mg/kg. At the scheduled sacrifice, there were no hematological changes at any dose, but blood biochemical examination of the 200 mg/kg group showed increases in -GTP in both sexes and total protein in males. In addition, significant increase in relative liver weights was noted in 9% of the females in the 60 mg/kg group and in 21–23% of both males and females in the 200 mg/kg group. On histopathological examination, slight hypertrophy of centrilobular hepatocytes was found in one female of the 60 mg/kg group, and in four males and three females from the 200 mg/kg group. During the recovery-maintenance period, no clinical signs were observed and the lowered body weights showed a tendency for recovery. In parameters for physical and sexual development and reflex ontogeny, no definitive changes were detected. At the end of the recovery-maintenance period, no chemical-related changes, also in urinalysis data, were found in any dose group.

The results of the newborn rat study of 2TBP are summarized in Table 2. Since clinical signs and histopathological changes in the liver were observed in the 60 mg/kg group, the NOAEL was concluded to be 20 mg/kg/day.

Young rat study

Ataxic gait were observed sporadically during the dosing period in nine males and 12 females, and decrease in locomotor activity in two females from the 500 mg/kg group. During the dosing period, there were no changes in body weight, food consumption, and urinalysis data. At the scheduled sacrifice, hematological and blood biochemical examination also showed no changes. Eighteen to 19% increases were found in relative liver weights of both sexes receiving 500 mg/kg, but no histopathological changes in liver were observed at any dose. No chemical-related changes were noted during and at the end of the recovery period.

Table 1 Clinical signs observed during the dosing period in the newborn rat study of 2-*tert*-butylphenol

	Dose (mg/kg/day)			
	0	20	60	200
No. animals (Male/Female)	12/12	12/12	12/12	12/12
No. animals with clinical signs				
Decrease in locomotor activity	0/0	0/0	1†/0	12/12
Ataxic gait	0/0	0/0	0/0	4/6
Deep respiration	0/0	0/0	0/0	12/12
Tremors	0/0	0/0	0/0	2/4
Muscle weakness	0/0	0/0	0/0	12/12
Emaciation	0/0	0/0	0/0	2/2
Pale skin	0/0	0/0	0/0	4/2

†Observed only on the first dosing day.

Table 2 Summary of the results of the newborn and young rat study of 2-*tert*-butylphenol

Newborn rat study				
Dose (mg/kg/day)	20	60	200	
Clinical signs	–	M: Decrease in locomotor activity	Various†	
Body weight changes	–	–	8–17%	
Blood biochemical changes	–	–	GTP , M: TP	
Changes in relative organ weights	–	F: Liver 9%	Liver 21–23%	
Histopathological findings in liver				
– Slight centrilobular hypertrophy of hepatocytes	–	M: 0/6, F: 1/6	M: 4/6, F: 3/6	
Young rat study				
Dose (mg/kg/day)	4	20	100	500
Clinical signs	–	–	–	Ataxic gait F: Decrease in locomotor activity
Body weight changes	–	–	–	–
Blood biochemical changes	–	–	–	–
Changes in relative organ weights	–	–	–	Liver 18–19%
Histopathological findings	n.d.	n.d.	n.d.	–

Statistically significant increases ($P < 0.05$) in body weights, blood biochemical parameters and relative organ weights are shown as , while decreases are shown as . Data on histopathological findings are given as no. of animals with the findings/no. of animals examined, according to sex. Changes observed only in males or females are shown as 'M' or 'F', respectively, while neither 'M' nor 'F' is mentioned in the case of changes noted in both sexes. No chemical-related changes were observed in developmental parameters (conducted only in newborn rat study), urinalysis (only in young rat study), and hematological parameters. †Decrease in locomotor activity, ataxic gait, deep respiration, tremors, muscle weakness, emaciation, and pale skin were observed, as shown in Table 1. GTP, -GTP; TP, total protein; –, no change; n.d., not determined.

A summary of the results of the young rat study of 2TBP is given in Table 2. The NOAEL was concluded to be 100 mg/kg/day, at which no changes were observed.

2,4-di-*tert*-butylphenol (DTBP)

Newborn rat study

Two males and one female of the 300 mg/kg group were found dead on dosing days 3, 4, and 7. In this group, decrease in locomotor activity (12 males and 12 females), bradypnea (10 males and 10 females), and hypothermia (one male) were observed from the first dosing day, but then the incidence decreased, with disappearance after dosing day 7. Body weights of the 300 mg/kg group were lowered by 15–25% in males and by 9–20% in females during the dosing period, compared with the control values. There were no definitive changes in parameters for physical development and reflex ontogeny in any dose group. At the scheduled sacrifice, blood biochemical examination showed an increase in total bilirubin and a decrease in the A/G ratio in both sexes, an increase in -GTP in males, and an increase in total protein and BUN in females of the 300 mg/kg group. In the 300 mg/kg group, there was a 39–51% increase in relative liver weights, a 37–41% increase in relative kidney weights in both sexes, and a 24% decrease in relative spleen weights in males. In the 40 mg/kg group, 14% increases in relative weight of liver were found in females. On histopathological examination, various changes were observed in livers and kidneys in the 300 mg/kg group, as shown in Table 3. Furthermore, periportal fatty degeneration of hepatocytes was evident in one female given 40 mg/kg, and basophilic tubules in kidneys in one animal of each sex receiving 40 mg/kg and one control group male. Regarding parameters of sexual development, a slight delay in preputial separation was noted in the 300 mg/kg group (the incidences were 0/5, compared with 2/6 in the control group at PND 42 [recovery-maintenance day 21]; 0/5, 3/6 at PND 43; 2/5, 5/6 at PND 44; 2/5, 6/6 at PND 46; 4/5, 6/6 at PND 47; and 5/5, 6/6 at PND 48). During this observation period, body weights were lowered by approximately 10% in males given 300 mg/kg than control levels, which was not statistically significant. In the last week of the recovery-maintenance period, there were no chemical-related changes on urinalysis in any dose group. At the end of the recovery period, changes noted in the scheduled-sacrifice group were not observed except for histopathological changes in the kidneys, significant in the 300 mg/kg group (Table 3).

A summary of the results of the newborn rat study of DTBP is shown in Table 4. Since fatty degeneration of hepatocytes and increase in liver weight were demonstrated at 40 mg/kg, the NOAEL was concluded to be 5 mg/kg/day.

Young rat study

No chemical-related changes were found in general condition, body weight, and food consumption at any dose. On urinalysis at the fourth week of dosing, an increase in urine volume, and a decrease in specific gravity and osmotic pressure were noted in both sexes of the 300 mg/kg group. At the scheduled sacrifice, hematological examination showed a decrease in hemoglobin and hematocrit, an increase in segmented neutrophils in females, and prolongation of PT and APTT in males at 300 mg/kg. On blood biochemical examination, there was an increase in total bilirubin in males given 300 mg/kg, and an increase in total cholesterol and phospholipid in females given 75 mg/kg and above. For organ weights, there were

Table 3 Histopathological findings for the newborn rat study of 2,4-di-*tert*-butylphenol

		Scheduled-sacrifice group				Recovery-maintenance group†	
Dose (mg/kg/day)	Grade	0	5	40	300	0	300
No. of animals examined (Male/Female)		6/6	6/6	6/6	5/6	6/6	5/5
Liver							
– Fatty degeneration of periportal hepatocytes	+	0/0	0/0	0/1	0/0	0/0	0/0
	++	0/0	0/0	0/0	3/4	0/0	0/0
	+++	0/0	0/0	0/0	2/2	0/0	0/0
Kidneys							
– Basophilic tubules	+	1/0	n.d.	1/1	4/4	0/0	3/0
– Granular casts	+	0/0	n.d.	0/0	4/2	0/0	0/0
– Cystic dilatation of collecting tubules	+	0/0	n.d.	0/0	0/0	0/0	5/4
	++	0/0	n.d.	0/0	3/4	0/0	0/0
	+++	0/0	n.d.	0/0	2/2	0/0	0/0
– Cellular infiltration of neutrophils	+	0/0	n.d.	0/0	2/1	0/0	1/0
	++	0/0	n.d.	0/0	1/1	0/0	1/0
	+++	0/0	n.d.	0/0	1/1	0/0	0/0

†No histopathological examination was conducted at 5 and 40 mg/kg in the recovery-maintenance group. +, mild; ++, moderate; +++, marked; n.d., not determined.

increases in relative liver weights by 40–43% in both sexes given 300 mg/kg, and by 13% in females receiving 75 mg/kg. On histopathological examination, mild to marked changes in livers and kidneys were observed in both sexes from the 300 mg/kg group, as shown in Table 5. At the end of the recovery period, the increase in total cholesterol and phospholipid and renal histopathological changes observed in the scheduled-sacrifice group remained significant in the highest-dose group (Table 5).

The results of the young rat study are summarized in Table 4. Based on increase in the relative liver weights with some changes in blood biochemical parameters in females given 75 mg/kg, the NOAEL was concluded to be 20 mg/kg/day.

DISCUSSION

During development, many rapid and complex biological changes occur, which can have profound consequences on sensitivity to the effects of exogenous chemicals (Scheuplein *et al.* 2002). Although the neonatal body at birth is reasonably well prepared for the abrupt changes associated with parturition, and most functional systems possess a significant portion of their adult capacity (Dourson *et al.* 2002), it is known that the various functions remain immature in early postnatal period and that some organs and tissues, especially in the nervous, immune and reproductive systems, continue to develop after birth (NAS 1993). Therefore, it is important to evaluate toxic effects by exposure to chemicals during the early postnatal period as well as the fetal period for comprehensive risk assessment. However, economic issues and lack of human resources, arising from practical difficulties regarding protocols, have hindered routine implementation of toxicity studies using newborn animals. Our series of comparative analyzes on susceptibility of the newborn are therefore of particular importance for risk assessment.

In the present study on 2TBP and DTBP, there were no clear differences in toxicity profiles between the newborn and young rats in either case. For 2TBP, clinical signs such as a decrease in locomotor activity and ataxic gait, and effects on liver such as an increase in organ weight were observed. In the DTBP case, hepatic and renal toxicity (histopathological changes, increase in organ weight, etc.) were noted. As a characteristic effect of DTBP on male sexual development, slight delay in preputial separation was also observed in the newborn rat study. Preputial separation, an androgen-dependent process which is an early marker of puberty, represents a reliable non-invasive indicator of chemical-induced perturbation of male pubertal development in the rat (Gaytan *et al.* 1988). However, it is known that decreased body weights can result in non-specific delay in puberty (Ashby & Lefevre 2000). Since DTBP lowered body weights in the period of observation of preputial separation and there were no DTBP-related changes in weights or histopathology of the testes and epididymides, well known to be essentially androgen-dependent, no specific effect on male sexual development could be concluded in the present study. As for NOAELs of both chemicals, clear differences were observed between newborn and young rats, with values of 20 and 5 mg/kg/day in newborn rats, and 100 and 20 mg/kg/day in young rats for 2TBP and DTBP, respectively. Therefore, the susceptibility was four- to five-fold higher in newborn than in young rats.

Our previous analysis of 1,3-dibromopropane and 1,1,2,2-tetrabromoethane (Hirata-Koizumi *et al.* 2005) showed dose–response curves to be very different between newborn and young rats. The same was recently reported for the widely used organophosphorus insecticide, chlorpyrifos (Zheng *et al.* 2000), as well as pyrethroid insecticides (Shafer *et al.* 2005). These data showed the importance of estimating unequivocally toxic levels (UETLs), defined for our comparative toxicity analysis as equivalent toxic doses inducing clear toxicity, including death, clinical toxic signs,

Table 4 Summary of the results of the newborn and young rat study of 2,4-di-*tert*-butylphenol

Newborn rat study				
Dose (mg/kg/day)	5	40	300	
Death	–	–	M: 2/12, F: 1/12	
Clinical signs	–	–	Decrease in locomotor activity bradypnea, hypothermia	
Body weight changes	–	–	9–25%	
Urinalysis	n.d.	n.d.	n.d.	
Hematological changes	–	–	–	
Blood biochemical changes	–	–	Various†	
Changes in relative organ weights	–	F: Liver 14%	Liver 39–51% , Kidney 37–41% M: Spleen 24%	
Histopathological findings	–	F: Fatty degeneration in liver	Various changes in liver and kidney‡	
Developmental parameters	–	–	Slight delay in preputial separation	
Young rat study				
Dose (mg/kg/day)	5	20	75	300
Death	–	–	–	–
Clinical signs	–	–	–	–
Body weight changes	–	–	–	–
Urinalysis	–	–	–	UV SG OP
Hematological changes	–	–	–	Various§
Blood biochemical changes	–	–	F: Tcho Pho	M: TB F: Tcho Pho
Changes in relative organ weights	–	–	F: Liver 13%	Liver 40–43%
Histopathological findings	n.d.	n.d.	–	Various changes in liver and kidney¶

Data on death are shown as no. of dead animals/no. of animals examined, according to sex. Statistically significant increases ($P < 0.05$) in body weights, urinalysis and blood biochemical parameters, and relative organ weights are shown as , while decreases are shown as . Changes observed only in males or females are shown as 'M' or 'F', respectively, while neither 'M' nor 'F' is mentioned in the case of changes noted in both sexes. †Increase in total bilirubin and decrease in the A/G ratio in both sexes, increase in -GTP in males, and increase in total protein and BUN in females were noted. ‡Various changes were observed as shown in Table 3. §Various hematological changes were noted such as decrease in hemoglobin and hematocrit and increase in segmented neutrophils in females and prolongation of PT and APTT in males. ¶Various changes were observed as shown in Table 5. OP: osmotic pressure; Pho: phospholipid; SG: specific gravity; TB: total bilirubin; Tcho: total cholesterol; UV: urine volume; –: no change; n.d.: not determined.

or critical histopathological damage (Koizumi *et al.* 2001). We here tried to apply this UETL approach to the present study. For 2TBP, clinical signs such as decrease in locomotor activity and ataxic gait were noted in most of the animals given 200 mg/kg (newborn rats) and 500 mg/kg (young rats) (Table 2). Furthermore, a 8–17% lowering of body weight was observed at 200 mg/kg in newborn rats, but not in the young rat study. Therefore, equivalent toxic effects to these observed at 500 mg/kg in young rats might be expected to appear at 100–150 mg/kg in newborn animals. The UETLs were concluded to be 100–150 and 500 mg/kg/day in newborn and young rats, respectively. In the case of DTBP, clear toxicity was observed at the top dose of 300 mg/kg in both newborn and young rat studies (Table 4), but the level of severity was very different, for example, deaths were only noted in the newborn cases. It was considered difficult to estimate the UETLs from the results of main studies only. However, the most critical endpoint for toxicity, mortality, was also noted at 100 mg/kg and more, and 500 mg/kg, in the dose-finding studies of newborn and young rats, respectively. Therefore, it would be possible to estimate the appropriate UETLs as the minimum lethal dose by taking the results of the dose-finding studies into consideration. The UETLs were concluded to be 100 mg/kg/day for the newborn, and 500 mg/kg/day for young rats, at which one out of eight rats was found dead in both cases. These analyzes of UETLs, considering equivalence in toxic degree, showed 3.3–5.0 times higher susceptibility of newborn rats to 2TBP and DTBP than young rats, consistent with our analytical results for NOAELs.

Higher susceptibility of newborn rats was also demonstrated in our previous analyzes of five phenols (4-nitrophenol, 2,4-dinitrophenol, 3-aminophenol, 3-methylphenol and 2,4,6-trinitrophenol) (Koizumi *et al.* 2001, 2002, 2003; Takahashi *et al.* 2004), considered mainly due to their poor metabolic and excretory capacity (Horster 1977; Cresteil *et al.* 1986). It has actually been reported that UDP-glucuronyltransferase and sulfotransferase activities, when 4-nitrophenol is used as the substrate, are lower in microsomes prepared from livers of newborn rats, and that the elimination rate of 2,4-dinitrophenol from serum of newborn rabbits is markedly slower than in young adults (Gehring & Buerge 1969; Matsui & Watanabe 1982). Unfortunately, there is no information on the toxicity mechanism and toxicokinetics of both 2TBP

Table 5 Histopathological findings for the young rat study of 2,4-di-*tert*-butylphenol

		Scheduled-sacrifice group†			Recovery group	
Dose (mg/kg/day)	Grade	0	75	300	0	300
No. of animals examined (Male/Female)		6/6	6/6	6/6	6/6	6/6
Liver						
– Centrilobular hypertrophy of hepatocytes	+	0/0	0/0	4/4	0/0	0/0
Kidneys						
– Basophilic tubules	+	0/0	0/0	1/4	0/0	3/1
	++	0/0	0/0	4/0	0/0	2/0
	+++	0/0	0/0	1/1	0/0	1/0
– Granular casts	+	0/0	0/0	5/2	0/0	4/0
	++	0/0	0/0	1/1	0/0	0/0
– Proteinaceous casts	+	0/0	0/0	5/1	0/0	2/0
	++	0/0	0/0	1/0	0/0	0/0

†No histopathological examination was conducted for the 5 and 20 mg/kg scheduled-sacrifice groups. +, mild; ++, moderate; +++, marked.

and DTBP; however, the immature functions involved in the toxicokinetics in newborn rats would be implicated in the higher susceptibility, as in the case of five phenols previously analyzed. While there are very little data on toxicokinetics of environmental chemicals in the newborn, relatively plentiful information has been reported in humans for pharmaceuticals which are clinically applied during the early postnatal period. Recently, Ginsberg *et al.* (2002) conducted comparative analysis of pharmacokinetic parameters for 45 drugs in both children and adults, and showed half-lives in children aged two months or under to generally be two-fold longer than in adults.

As for the susceptibility of the newborn to toxicity of chemicals, although it is generally important to take the sensitivity of target organs and tissues themselves (toxicodynamics) into consideration besides toxicokinetics, there are insufficient data on differences between newborn and young/adult animals. For appearance of toxicity, which is the outcome of toxicokinetics and toxicodynamics, some comparative studies have relied on LD_{50} values (Goldenthal 1971; Sheehan & Gaylor 1990). However, it is not considered that information on acute toxicity at lethal dosage is appropriate when considering the susceptibility of newborn in risk assessment, because dose–response curves could differ, as mentioned above. With prolonged, subtoxic doses, which are basis for TDI or ADI, our series of comparative studies constitute the first systematic assessment, providing an important base for development of new methods of risk assessment of susceptibility of the newborn.

In conclusion, clinical signs and effects on the liver were observed for 2TBP, and hepatic and renal toxicity for DTBP. Although there were no clear differences in toxicity profiles between the newborn and young rats for both chemicals, the toxicity levels differed markedly. The susceptibility of the newborn to these chemicals appears to be 4–5 times higher than that of young animals.

ACKNOWLEDGMENT

The authors gratefully acknowledge the financial support of the Office of Chemical Safety, Pharmaceutical and Medical Safety Bureau, Ministry of Health, Labor and Welfare, Japan.

REFERENCES

Adams J (1986) Methods in behavioral teratology. In: Riley EP, Vorhees CV (eds). *Handbook of Behavioral Teratology*. Plenum Press, New York, pp. 67–97.

Ashby J, Lefevre PA (2000) The peripubertal male rat assay as an alternative to the Hershberger castrated male rat assay for the detection of anti-androgens, oestrogens and metabolic modulators. *J Appl Toxicol* **20**: 35–47.

Bartlett MS (1937) Properties of sufficiency and statistical tests. *Proc R Soc Lond Ser A* **160**: 268–282.

Chemical Products' Handbook (2004) *14504 No Kagakushohin*. [Chemical Products of 14504]. The Chemical Daily Co., Ltd, Tokyo. (In Japanese).

Cresteil T, Beaune P, Celier C, Leroux JP, Guengerich FP (1986) Cytochrome P-450 isoenzyme content and monooxygenase activities in rat liver: Effect of ontogenesis and pretreatment by phenobarbital and 3-methylcholanthrene. *J Pharmacol Exp Ther* **236**: 269–276.

Dourson M, Charnley G, Scheuplein R (2002) Differential sensitivity of children and adults to chemical toxicity. II. Risk and regulation. *Regul Toxicol Pharmacol* **35**: 448–467.

Dunnett CW (1964) New tables for multiple comparisons with a control. *Biometrics* **20**: 482–491.

Fisher RA (1922) On the interpretation of chi-square from contingency tables and the calculation of P. *J R Stat Soc* **85**: 87–94.

Fukuda N, Ito Y, Yamaguchi M *et al.* (2004) Unexpected nephrotoxicity induced by tetrabromobisphenol A in newborn rats. *Toxicol Lett* **150**: 145–155.

Gaytan F, Bellido C, Aguilar R, Aguilar E (1988) Balanopreputial separation as an external sign of puberty in the rat: Correlation with histologic testicular data. *Andrologia* **20**: 450–453.

Gehring PJ, Buerge JF (1969) The distribution of 2,4-dinitrophenol relative to its cataractogenic activity in ducklings and rabbits. *Toxicol Appl Pharmacol* **15**: 574–592.

Ginsberg G, Hattis D, Sonawane B *et al.* (2002) Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. *Toxicol Sci* **66**: 185–200.

Goldenthal EI (1971) A compilation of LD50 values in newborn and adult animals. *Toxicol Appl Pharmacol* **18**: 185–207.

Hirata-Koizumi M, Kusuoka O, Nishimura N *et al.* (2005) Susceptibility of newborn rats to hepatotoxicity of 1,3-dibromopropane and 1,1,2,2-tetrabromomethane, compared with young rats. *J Toxicol Sci* **30**: 29–42.

Hollander M, Wolfe DA (1973) *Nonparametric Statistical Methods*. John Wiley and Sons, New York.